chr3:138652698:> Detail (hg38)
Information
Genome
Assembly | Position |
---|---|
hg19 | chr3:138,371,540-138,553,770 |
hg38 | chr3:138,652,698-138,834,928 |
HGVS
Type | Transcript | Protein |
---|---|---|
Summary
MGeND
Clinical significance | |
Variant entry | |
GWAS entry | |
Disease area statistics | Show details |
Frequency
[No Data.]
Prediction
[No Data.]
ClinVar
Clinical Significance | |
Review star | [No Data.] |
Show details |
Links
Disease area statistics
[No Data.]
MGeND
[No Data.]
ClinVar
[No Data.]
CIViC
[No Data.]
DisGeNET
Score | Disease name | Description | Source | Pubmed | Links |
---|---|---|---|---|---|
0.005 | renal cell carcinoma | Curcumin significantly enhances dual PI3K/Akt and mTOR inhibitor NVP-BEZ235-indu... | BeFree | 24743574 | Detail |
0.005 | renal cell carcinoma | We genotyped 70 genes involved in the pathogenesis of renal-cell carcinoma (incl... | BeFree | 24767687 | Detail |
0.005 | renal cell carcinoma | The phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT) pathway has been ide... | BeFree | 25757764 | Detail |
0.005 | renal cell carcinoma | PI3Kβ inhibitor TGX221 selectively inhibits renal cell carcinoma cells with both... | BeFree | 25853938 | Detail |
0.005 | renal cell carcinoma | Taken together, our findings indicate that ghrelin can activate Snail function v... | BeFree | 25925728 | Detail |
0.004 | squamous cell carcinoma | Importantly, the level of miR-508 correlates with poor survival and activated PI... | BeFree | 25099196 | Detail |
0.004 | squamous cell carcinoma | Moreover, blocking the whole PI3K-AKT-mTOR pathway with the PI3K/mTOR dual inhib... | BeFree | 26216950 | Detail |
<0.001 | Carcinoma, Transitional Cell | NA | BeFree | Detail | |
<0.001 | Cardiomyopathy, Dilated | NA | BeFree | Detail | |
<0.001 | cerebral infarction | NA | BeFree | Detail | |
0.003 | Malignant tumor of cervix | Taken together, our data suggest that anti-VEGFa treatment in cervical cancer ma... | BeFree | 25135429 | Detail |
0.003 | Malignant tumor of cervix | CD38 is highly expressed and affects the PI3K/Akt signaling pathway in cervical ... | BeFree | 25310288 | Detail |
0.003 | Malignant tumor of cervix | Peroxisome proliferator-activated receptor-gamma agonist 4-O-methylhonokiol indu... | BeFree | 25563418 | Detail |
0.003 | Malignant tumor of cervix | The phosphatase and tensin homolog deleted on chromosome 10 (PTEN) protein is pr... | BeFree | 25738254 | Detail |
0.003 | Malignant tumor of cervix | Butein suppresses cervical cancer growth through the PI3K/AKT/mTOR pathway. | BeFree | 25962638 | Detail |
<0.001 | Chikungunya Fever | In cells infected with the closely related chikungunya virus (CHIKV), the PI3K-A... | BeFree | 26339054 | Detail |
0.001 | chondrosarcoma | Stimulation of chondrosarcoma with CCL5 augmented PI3K and Akt phosphorylation, ... | BeFree | 25301739 | Detail |
<0.001 | chordoma | NA | BeFree | Detail | |
<0.001 | choriocarcinoma | NA | BeFree | Detail | |
<0.001 | Congenital chromosomal disease | In acute myeloid leukemia (AML), several signaling pathways such as the phosphat... | BeFree | 25322685 | Detail |
<0.001 | colitis | NA | BeFree | Detail | |
<0.001 | Colonic Neoplasms | NA | BeFree | Detail | |
0.012 | colorectal carcinoma | The added predictive value of additional biomarkers in the RAS-RAF-MAPK and PI3K... | BeFree | 24666267 | Detail |
0.012 | colorectal carcinoma | The role of c2orf68 and PI3K/Akt/mTOR pathway in human colorectal cancer. | BeFree | 25023051 | Detail |
0.012 | colorectal carcinoma | These data indicate that the capacity of retinol to inhibit PI3K activity confer... | BeFree | 25356626 | Detail |
0.012 | colorectal carcinoma | We conclude that cPLA2α is required for sustaining AKT phosphorylation at Ser473... | BeFree | 25365190 | Detail |
0.012 | colorectal carcinoma | Inhibitors against KRAS signaling mediators, namely, PI3K (phosphatidylinositol ... | BeFree | 25389372 | Detail |
0.012 | colorectal carcinoma | PTEN inactivation by mutation or allelic loss also occurs in CRCs. miR‑135b was ... | BeFree | 25571954 | Detail |
0.012 | colorectal carcinoma | The role of the PI3K pathway in colorectal cancer. | BeFree | 25591826 | Detail |
0.012 | colorectal carcinoma | Mutations in the RAS and PI3K pathways are associated with metastatic location i... | BeFree | 25920435 | Detail |
0.012 | colorectal carcinoma | Eight of these genes were linked to the Wnt, Hippo, TGF-β, EGF receptor, or PI3K... | BeFree | 26056301 | Detail |
<0.001 | Colorectal Neoplasms | NA | BeFree | Detail | |
<0.001 | Coronary Arteriosclerosis | bFGF regulates autophagy and ubiquitinated protein accumulation induced by myoca... | BeFree | 25787015 | Detail |
<0.001 | cystadenoma | NA | BeFree | Detail | |
<0.001 | Phyllodes Tumor | NA | BeFree | Detail | |
<0.001 | scleroderma | NA | BeFree | Detail | |
0.001 | Diabetes | NA | BeFree | Detail | |
0.002 | diabetes mellitus | NA | BeFree | Detail | |
0.010 | Diabetes Mellitus, Non-Insulin-Dependent | Effects of D-Pinitol on Insulin Resistance through the PI3K/Akt Signaling Pathwa... | BeFree,GAD | 26063468 | Detail |
<0.001 | Diabetic Nephropathy | Podocyte-specific genetic ablation of XBP1 or inducible expression of ATF6 in mi... | BeFree | 25754093 | Detail |
0.001 | endometriosis | NA | BeFree | Detail | |
<0.001 | Ependymoma | NA | BeFree | Detail | |
0.001 | Esophageal Neoplasms | Therefore, concomitant blockage of the ErbB2-PI3K pathway and the Hedgehog downs... | BeFree | 25435423 | Detail |
<0.001 | fetal alcohol syndrome | NA | BeFree | Detail | |
<0.001 | fibrosarcoma | NA | BeFree | Detail | |
<0.001 | fragile X syndrome | NA | BeFree | Detail | |
0.015 | glioblastoma | Moreover, TRIM24 regulates the expression of DNA repair enzyme O(6)-methylguanin... | BeFree | 24469053 | Detail |
0.015 | glioblastoma | ABT-263 (Navitoclax), an orally available small-molecule Bcl-2 inhibitor, and GD... | BeFree | 24757258 | Detail |
0.015 | glioblastoma | In this study, we used inhibitors to block specific signaling pathways, includin... | BeFree | 25048528 | Detail |
0.015 | glioblastoma | Application of a specific extracellular-related kinase 1/2 (ERK1/2) inhibitor, b... | BeFree | 25213694 | Detail |
0.015 | glioblastoma | However, due to the development of resistance mechanisms, kinase inhibition stud... | BeFree | 25256166 | Detail |
0.015 | glioblastoma | The EGFR and PI3K/mTORC1/2 pathways are frequently altered in glioblastoma (GBM)... | BeFree | 25316808 | Detail |
0.015 | glioblastoma | The activation of PI3K/Akt1 signaling pathway is involved in the proliferation o... | BeFree | 25501279 | Detail |
0.015 | glioblastoma | Further analyses revealed that Cyr61 seemed to activate PI3K/Akt/mTor signaling ... | BeFree | 25501701 | Detail |
0.010 | Glioma | TRIM24 promotes glioma progression and enhances chemoresistance through activati... | BeFree | 24469053 | Detail |
0.010 | Glioma | These results suggest that Liq treatment enhances glioma cell susceptibility to ... | BeFree | 25351348 | Detail |
0.010 | Glioma | Several studies have attempted to investigate the effects of combining the inhib... | BeFree | 25688137 | Detail |
0.010 | Glioma | The loss of MAGI3 expression in glioma may enhance the proliferation of glioma c... | BeFree | 26248734 | Detail |
<0.001 | IgA glomerulonephritis | NA | BeFree | Detail | |
<0.001 | granulosa cell tumor | NA | BeFree | Detail | |
<0.001 | Graves Disease | NA | BeFree | Detail | |
<0.001 | Hamartoma | NA | BeFree | Detail | |
<0.001 | Hamartoma Syndrome, Multiple | NA | BeFree | Detail | |
<0.001 | Heart Diseases | NA | BeFree | Detail | |
0.001 | Heart failure | NA | BeFree | Detail | |
0.001 | congestive heart failure | NA | BeFree | Detail | |
<0.001 | Atrial Septal Defects | NA | BeFree | Detail | |
<0.001 | Hemangiosarcoma | NA | BeFree | Detail | |
0.003 | hepatitis C | NA | BeFree,GAD | Detail | |
<0.001 | Herpes Simplex Infections | NA | BeFree | Detail | |
<0.001 | Von Hippel-Lindau syndrome | NA | BeFree | Detail | |
<0.001 | Histiocytosis, Langerhans-Cell | NA | BeFree | Detail | |
0.004 | HIV Infections | NA | BeFree,GAD | Detail | |
<0.001 | Hodgkin Disease | NA | BeFree | Detail | |
<0.001 | hyperglycemia | NA | BeFree | Detail | |
<0.001 | hypoglycemia | NA | BeFree | Detail | |
<0.001 | Immunologic Deficiency Syndromes | NA | BeFree | Detail | |
<0.001 | Immune System Diseases | This article highlights recent progress in characterizing the molecular mechanis... | BeFree | 25573003 | Detail |
0.001 | influenza | This novel mechanism of Dlg1 subversion by adenovirus to dysregulate PI3K could ... | BeFree | 24788832 | Detail |
0.002 | Insulin resistance | NA | GAD | Detail | |
<0.001 | Intestinal Neoplasms | NA | BeFree | Detail | |
<0.001 | intestinal pseudo-obstruction | NA | BeFree | Detail | |
0.002 | ischemia | In this study, we examined the effect of Ginsenoside Rb1 (GRb1) on ischemia/repe... | BeFree | 25257523 | Detail |
<0.001 | Keloid | NA | BeFree | Detail | |
<0.001 | Kidney Failure, Acute | NA | BeFree | Detail | |
<0.001 | Kidney Neoplasm | NA | BeFree | Detail | |
<0.001 | leiomyosarcoma | NA | BeFree | Detail | |
0.005 | leukemia | In the present study, we have shown for the first time that HBA decreased the ex... | BeFree | 25299784 | Detail |
0.005 | leukemia | The PI3K/Akt signaling pathway is constitutively activated in various leukemias. | BeFree | 26194899 | Detail |
0.003 | chronic lymphocytic leukemia | Altogether, these results underline the key role of PI3K/AKT pathway in the gene... | BeFree | 24825182 | Detail |
0.003 | chronic lymphocytic leukemia | The phosphoinositide-3-kinase (PI3K)-delta and gamma inhibitor, IPI-145 (Duvelis... | BeFree | 25917267 | Detail |
<0.001 | Acute Erythroblastic Leukemia | NA | BeFree | Detail | |
<0.001 | hairy cell leukemia | NA | BeFree | Detail | |
0.002 | Acute lymphocytic leukemia | NA | BeFree | Detail | |
<0.001 | Leukemia, Mast-Cell | NA | BeFree | Detail | |
0.008 | Leukemia, Myelocytic, Acute | Importantly, emodin was demonstrated as a new inhibitor of PI3K/Akt in AML cells... | BeFree | 25174432 | Detail |
0.008 | Leukemia, Myelocytic, Acute | Inhibiting rescue pathways could improve the therapeutic efficacy of PI3K-target... | BeFree | 25322685 | Detail |
0.008 | Leukemia, Myelocytic, Acute | In the primary AML sample, we investigated the cell responses to ex vivo stimula... | BeFree | 25598437 | Detail |
0.008 | Leukemia, Myelocytic, Acute | The Ras/Raf/MAPK and PI3K/Akt/mTOR pathways are key signaling cascades involved ... | BeFree | 26044548 | Detail |
0.001 | myeloid leukemia | NA | BeFree | Detail | |
0.002 | Myeloid Leukemia, Chronic | The fusion gene bcr-abl develops chronic myeloid leukemia (CML), and stimulates ... | BeFree | 25644089 | Detail |
<0.001 | Leukemia, Myeloid, Chronic-Phase | NA | BeFree | Detail | |
<0.001 | Leukemia, T-Cell | NA | BeFree | Detail | |
<0.001 | Adult T-Cell Lymphoma/Leukemia | NA | BeFree | Detail | |
<0.001 | lipodystrophy | NA | BeFree | Detail | |
<0.001 | lipomatosis | NA | BeFree | Detail | |
<0.001 | liposarcoma | NA | BeFree | Detail | |
<0.001 | liver cirrhosis | NA | BeFree | Detail | |
<0.001 | Liver diseases | NA | BeFree | Detail | |
0.002 | Liver neoplasms | HBx induced AFP receptor expressed to activate PI3K/AKT signal to promote expres... | BeFree | 25943101 | Detail |
<0.001 | Lung Neoplasms | NA | BeFree | Detail | |
<0.001 | Lupus Erythematosus, Systemic | NA | BeFree | Detail | |
0.003 | lymphoma | NA | BeFree | Detail | |
<0.001 | Lymphoma, Follicular | NA | BeFree | Detail | |
<0.001 | Lymphoproliferative Disorders | NA | BeFree | Detail | |
<0.001 | Waldenstrom Macroglobulinemia | NA | BeFree | Detail | |
0.010 | Malignant neoplasm of stomach | In conclusion, knockdown of the c‑Met gene promoted gastric cancer cell apoptosi... | BeFree | 25395073 | Detail |
0.010 | Malignant neoplasm of stomach | Mechanically, PTP1B promotes gastric cancer cell proliferation, survival and inv... | BeFree | 25590580 | Detail |
0.010 | Malignant neoplasm of stomach | Therefore, our studies reveal for the first time that inhibition of the PI3K-Akt... | BeFree | 25640278 | Detail |
0.010 | Malignant neoplasm of stomach | Hepatocyte growth factor (HGF) upregulates heparanase expression via the PI3K/Ak... | BeFree | 25727320 | Detail |
<0.001 | mastocytosis | NA | BeFree | Detail | |
0.002 | medulloblastoma | Targeting the PI3K/AKT/mTOR signaling pathway in medulloblastoma. | BeFree | 25601471 | Detail |
0.002 | medulloblastoma | The impact of RNA interference (RNAi)-mediated silencing of PI3K isoforms p110α ... | BeFree | 25915540 | Detail |
<0.001 | multiple endocrine neoplasia type 2B | NA | BeFree | Detail | |
<0.001 | meningioma | NA | BeFree | Detail | |
0.001 | Mesothelioma | NA | BeFree | Detail | |
<0.001 | Metabolic Diseases | Recent attention has focused on the role of phosphatidylinositol 3-kinase (PI3K)... | BeFree | 25512233 | Detail |
0.004 | multiple myeloma | Cancers like multiple myeloma (MM), which display elevated activity in key trans... | BeFree | 25197055 | Detail |
0.004 | multiple myeloma | Furthermore, our results demonstrated that the enforced expression of miR-145 in... | BeFree | 25369735 | Detail |
0.004 | multiple myeloma | Previously we showed that tetraspanin overexpression in MM cell lines attenuated... | BeFree | 25422161 | Detail |
<0.001 | Mycobacterium Infections | NA | BeFree | Detail | |
<0.001 | mycosis fungoides | In situ assessment of PI3K and PTEN alterations in mycosis fungoides: correlatio... | BeFree | 25267489 | Detail |
<0.001 | myelofibrosis | NA | BeFree | Detail | |
<0.001 | Myeloproliferative disease | Herein, we will review the clinically relevant inhibitors of the PI3K pathway th... | BeFree | 26062813 | Detail |
<0.001 | myocardial infarction | NA | BeFree | Detail | |
0.015 | Neoplasm Metastasis | Mechanistically, knockdown of FAP inactivated PTEN/PI3K/AKT and Ras-ERK and its ... | BeFree | 24722280 | Detail |
0.015 | Neoplasm Metastasis | IL-7 splicing variant IL-7δ5 induces EMT and metastasis of human breast cancer c... | BeFree | 24770666 | Detail |
0.015 | Neoplasm Metastasis | Molecular profiling of patient-matched brain and extracranial melanoma metastase... | BeFree | 24803579 | Detail |
0.015 | Neoplasm Metastasis | However, the mechanisms and specific functions of PI3K isoforms in tumor invasio... | BeFree | 24837077 | Detail |
0.015 | Neoplasm Metastasis | NOX4 promotes non-small cell lung cancer cell proliferation and metastasis throu... | BeFree | 24946933 | Detail |
0.015 | Neoplasm Metastasis | Yet, little is known concerning the role of the PI3K/Akt/Snail-dependent pathway... | BeFree | 25070581 | Detail |
0.015 | Neoplasm Metastasis | First-in-human study of CH5132799, an oral class I PI3K inhibitor, studying toxi... | BeFree | 25231405 | Detail |
0.015 | Neoplasm Metastasis | Overexpression of ribonuclease inhibitor defines good prognosis and suppresses p... | BeFree | 25257839 | Detail |
0.015 | Neoplasm Metastasis | These data indicate that the capacity of retinol to inhibit PI3K activity confer... | BeFree | 25356626 | Detail |
0.015 | Neoplasm Metastasis | These findings suggest that CEACAM6 enhances invasion and metastasis in GC by pr... | BeFree | 25398131 | Detail |
0.015 | Neoplasm Metastasis | These findings indicated that MALAT1 might suppress the tumor growth and metasta... | BeFree | 25431257 | Detail |
0.015 | Neoplasm Metastasis | In conclusion, this study suggested that EMT process can be triggered by the BMP... | BeFree | 25448881 | Detail |
0.015 | Neoplasm Metastasis | The EGFR/PI3K/PTEN/Akt/mTORC pathway plays prominent roles in malignant transfor... | BeFree | 25453219 | Detail |
0.015 | Neoplasm Metastasis | SPOCK1 as a potential cancer prognostic marker promotes the proliferation and me... | BeFree | 25623055 | Detail |
0.015 | Neoplasm Metastasis | The phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR... | BeFree | 25677064 | Detail |
0.015 | Neoplasm Metastasis | Together, these results demonstrate that HGF/c-met can activate PI3K/Akt and dow... | BeFree | 25727320 | Detail |
0.015 | Neoplasm Metastasis | Mechanistic studies further revealed that VAV3 overexpression could dysregulate ... | BeFree | 25791293 | Detail |
<0.001 | Embryonal Neoplasm | NA | BeFree | Detail | |
<0.001 | Neoplastic Syndromes, Hereditary | NA | BeFree | Detail | |
<0.001 | nephroblastoma | NA | BeFree | Detail | |
<0.001 | neurilemmoma | We suggest that Nutlin-3, possibly in combination with FAK or PI3K inhibitors, c... | BeFree | 25217104 | Detail |
0.005 | neuroblastoma | Moreover, inhibitors of PI3K/mTOR and GLI signaling reduced neuroblastoma cell g... | BeFree | 25134527 | Detail |
0.005 | neuroblastoma | Molecular rationale for the use of PI3K/AKT/mTOR pathway inhibitors in combinati... | BeFree | 25228590 | Detail |
0.005 | neuroblastoma | We previously demonstrated that PI3K Class IIβ (PI3KC2β) and its regulator inter... | BeFree | 25622909 | Detail |
<0.001 | neurofibromatosis 1 | NA | BeFree | Detail | |
0.005 | obesity | This integrated view of PI3K functions may ultimately help to develop new therap... | BeFree,GAD | 25512233 | Detail |
<0.001 | Degenerative polyarthritis | NA | BeFree | Detail | |
0.003 | osteosarcoma | Knockdown of CXCR7 suppressed proliferation and invasion of OS cells through dec... | BeFree | 24969680 | Detail |
0.003 | osteosarcoma | The present results indicated that LY294002 inhibits the malignant phenotype of ... | BeFree | 25351625 | Detail |
0.003 | osteosarcoma | Complementary genomic approaches highlight the PI3K/mTOR pathway as a common vul... | BeFree | 25512523 | Detail |
0.003 | osteosarcoma | In conclusion, icariin possesses a reversal effect on multidrug resistance in MG... | BeFree | 25747987 | Detail |
0.016 | ovarian carcinoma | Re-expression of ARHI in ovarian cancer cells blocks signaling through the PI3K ... | BeFree | 24769729 | Detail |
0.016 | ovarian carcinoma | MicroRNA-497 suppresses angiogenesis by targeting vascular endothelial growth fa... | BeFree | 25176450 | Detail |
0.016 | ovarian carcinoma | Inhibiting the PI3K/AKT pathway may be a useful treatment for ovarian carcinoma. | BeFree | 25216292 | Detail |
0.016 | ovarian carcinoma | Moreover, LY294002, a potent and specific cell-permeable inhibitor of phosphatid... | BeFree | 25340291 | Detail |
0.016 | ovarian carcinoma | The PI3K/AKT/mTOR pathway as a therapeutic target in ovarian cancer. | BeFree | 25677064 | Detail |
0.001 | Pancreatic Neoplasm | NA | BeFree | Detail | |
<0.001 | papilloma | NA | BeFree | Detail | |
<0.001 | paraganglioma | NA | BeFree | Detail | |
<0.001 | pheochromocytoma | NA | BeFree | Detail | |
<0.001 | pituitary adenoma | NA | BeFree | Detail | |
<0.001 | Pituitary Neoplasms | NA | BeFree | Detail | |
<0.001 | polycystic ovary syndrome | In type 2 diabetes, obesity and PCOS, there is, although with some variation fro... | BeFree | 25123125 | Detail |
<0.001 | polycythemia vera | NA | BeFree | Detail | |
<0.001 | Adenomatous Polyposis Coli | PTEN inactivation by mutation or allelic loss also occurs in CRCs. miR‑135b was ... | BeFree | 25571954 | Detail |
<0.001 | Precancerous Conditions | NA | BeFree | Detail | |
<0.001 | Preleukemia | NA | BeFree | Detail | |
0.004 | Prostatic Neoplasms | NA | BeFree,LHGDN | Detail | |
<0.001 | pulmonary fibrosis | NA | BeFree | Detail | |
0.001 | retinoblastoma | Genome-wide analyses have identified four major signaling nodes that are most fr... | BeFree | 25070358 | Detail |
0.001 | retinoblastoma | PIK3R3, an isoform of class IA phosphoinositide 3-kinase (PI3K), specifically in... | BeFree | 25371235 | Detail |
0.002 | rhabdomyosarcoma | In the present study, we searched for combination therapies with the dual PI3K/m... | BeFree | 25637161 | Detail |
0.002 | rhabdomyosarcoma | Thus, combined GLI1/2 and PI3K/mTOR inhibition represents a promising novel appr... | BeFree | 25749378 | Detail |
0.010 | Diabetes Mellitus, Non-Insulin-Dependent | The aim of our study was to investigate whether common polymorphisms in the gene... | BeFree | 15127203 | Detail |
0.123 | schizophrenia | NA | BeFree,CTD_human,GAD | Detail | |
<0.001 | systemic scleroderma | NA | BeFree | Detail | |
<0.001 | Seizures | These data are the first to demonstrate that the inflammatory response induced b... | BeFree | 25903737 | Detail |
<0.001 | Septicemia | NA | BeFree | Detail | |
<0.001 | Dermatologic disorders | NA | BeFree | Detail | |
<0.001 | Skin lesion | We have already shown that AKT is activated in skin lesions in Mycosis Fungoides... | BeFree | 25267489 | Detail |
<0.001 | Stomach Neoplasms | NA | BeFree | Detail | |
<0.001 | Cerebrovascular accident | In conclusion, IL-8 stimulates VEGF production in hBM-MSCs in part via the PI3K/... | BeFree | 24797366 | Detail |
<0.001 | synovial sarcoma | NA | BeFree | Detail | |
0.080 | thrombosis | NA | RGD | Detail | |
0.002 | thymoma | NA | BeFree | Detail | |
0.002 | Thyroid Neoplasm | NA | BeFree | Detail | |
<0.001 | Chagas disease | NA | BeFree | Detail | |
<0.001 | tuberculosis | NA | BeFree | Detail | |
0.003 | tuberous sclerosis | In addition, the phosphoinositide-3-kinase (PI3K)/Akt/mammalian target of rapamy... | BeFree | 25153728 | Detail |
<0.001 | Attention Deficit Disorder | NA | BeFree | Detail | |
<0.001 | urticaria pigmentosa | NA | BeFree | Detail | |
0.001 | Virus Diseases | The phosphatidylinositol-3-kinase (PI3K) and Akt pathway is activated in host im... | BeFree | 25158146 | Detail |
0.001 | B-Cell Lymphomas | Many alterations directly or indirectly lead to activation of survival signaling... | BeFree | 24811162 | Detail |
0.001 | B-Cell Lymphomas | The oncogenic PI3K/serine-threonine kinase (PI3K/AKT) pathway is a downstream pa... | BeFree | 25862915 | Detail |
0.123 | diffuse large B-cell lymphoma | Inhibition of the PI3K/Akt/mTOR signaling pathway in diffuse large B-cell lympho... | BeFree,CTD_human | 25215588 | Detail |
<0.001 | Lymphoma, T-Cell, Cutaneous | NA | BeFree | Detail | |
<0.001 | peripheral T-cell lymphoma | We suggest that targeting the PI3K/AKT pathway may be a promising therapeutic st... | BeFree | 25862915 | Detail |
<0.001 | Liver failure | NA | BeFree | Detail | |
0.001 | acute leukemia | NA | BeFree | Detail | |
<0.001 | Rous Sarcoma | NA | BeFree | Detail | |
0.001 | Small cell carcinoma of lung | This study reveals a critical role for the PTEN/PI3K pathway in both SCLC and lu... | BeFree | 24482365 | Detail |
0.001 | Small cell carcinoma of lung | The PI3K/AKT/mTOR pathway is distinguishable in SCLC genomic alterations. | BeFree | 25122428 | Detail |
<0.001 | Oral Cavity Carcinoma | NA | BeFree | Detail | |
<0.001 | Myocardial Ischemia | bFGF regulates autophagy and ubiquitinated protein accumulation induced by myoca... | BeFree | 25787015 | Detail |
0.002 | Adenocarcinoma of lung (disorder) | These data identify RIT1 as a driver oncogene in a specific subset of lung adeno... | BeFree | 24469055 | Detail |
0.002 | Adenocarcinoma of lung (disorder) | This study reveals a critical role for the PTEN/PI3K pathway in both SCLC and lu... | BeFree | 24482365 | Detail |
0.002 | Adenocarcinoma of lung (disorder) | ERBB3-independent activation of the PI3K pathway in EGFR-mutant lung adenocarcin... | BeFree | 25596284 | Detail |
0.002 | Adenocarcinoma of lung (disorder) | Signaling through the Phosphatidylinositol 3-Kinase (PI3K)/Mammalian Target of R... | BeFree | 26023239 | Detail |
0.001 | esophageal carcinoma | Therefore, concomitant blockage of the ErbB2-PI3K pathway and the Hedgehog downs... | BeFree | 25435423 | Detail |
0.001 | esophageal carcinoma | Immunohistochemical and molecular analysis of PI3K/AKT/mTOR pathway in esophagea... | BeFree | 25912437 | Detail |
<0.001 | Malignant neoplasm of mouth | NA | BeFree | Detail | |
<0.001 | Malignant neoplasm of nasopharynx | NA | BeFree | Detail | |
<0.001 | Malignant neoplasm of gallbladder | We found that activation of the PI3K/Akt pathway was involved in the oncogenic f... | BeFree | 25623055 | Detail |
<0.001 | uterine cancer | NA | BeFree | Detail | |
<0.001 | Malignant neoplasm of brain | NA | BeFree | Detail | |
<0.001 | Secondary malignant neoplasm of lung | NA | BeFree | Detail | |
<0.001 | Obstructive chronic bronchitis with acute exacerbation | NA | BeFree | Detail | |
<0.001 | porphyria cutanea tarda | NA | BeFree | Detail | |
<0.001 | Saethre-Chotzen syndrome | NA | BeFree | Detail | |
<0.001 | LEOPARD Syndrome | NA | BeFree | Detail | |
0.004 | Tumor Progression | We propose the simultaneous activation of PLC-PKC-MEK1/2-ERK1/2 and PI3K pathway... | BeFree | 24909096 | Detail |
0.004 | Tumor Progression | These findings uncover a mechanism for constitutive PI3K/Akt activation in ESCC,... | BeFree | 25099196 | Detail |
0.004 | Tumor Progression | Our data showed that the PTEN/PI3K pathway was active in human ESCC tissues in v... | BeFree | 25175594 | Detail |
0.004 | Tumor Progression | The PI3K/AKT signal transduction pathway has distinct functional roles in tumor ... | BeFree | 25771729 | Detail |
<0.001 | Anaplastic carcinoma | NA | BeFree | Detail | |
<0.001 | Ki-1+ Anaplastic Large Cell Lymphoma | In addition to the commonly known AP-1 activators Mitogen-Activated Protein Kina... | BeFree | 25961698 | Detail |
<0.001 | hepatoblastoma | Anticancer effect of calycopterin via PI3K/Akt and MAPK signaling pathways, ROS-... | BeFree | 25060910 | Detail |
<0.001 | Liposarcoma, Myxoid | NA | BeFree | Detail | |
<0.001 | Rhabdomyosarcoma, Embryonal | NA | BeFree | Detail | |
<0.001 | Adenocarcinoma, Clear Cell | Crosstalk between PI3K and Ras pathways via protein phosphatase 2A in human ovar... | BeFree | 25756515 | Detail |
0.002 | Follicular thyroid carcinoma | NA | BeFree | Detail | |
<0.001 | Carcinoma, Endometrioid | Preclinical investigations have suggested that the PI3K/AKT/mTOR pathway is freq... | BeFree | 25677064 | Detail |
<0.001 | Carcinoma, Endometrioid | The efficacy of both PI3K and MEK inhibitors was evaluated in a model of endomet... | BeFree | 26232337 | Detail |
<0.001 | cholangiocarcinoma | NA | BeFree | Detail | |
<0.001 | Cystadenocarcinoma, Serous | NA | BeFree | Detail | |
<0.001 | Klatskin tumor | NA | BeFree | Detail | |
<0.001 | Rhabdoid Tumor | NA | BeFree | Detail | |
0.001 | Neuroendocrine Tumors | Neuroendocrine cancer cell lines are used to investigate therapeutic targets in ... | BeFree | 26087898 | Detail |
<0.001 | uveal melanoma | NA | BeFree | Detail | |
0.001 | Lip and oral cavity carcinoma | NA | BeFree | Detail | |
<0.001 | Macrocephaly | NA | BeFree | Detail | |
<0.001 | gallbladder carcinoma | We found that activation of the PI3K/Akt pathway was involved in the oncogenic f... | BeFree | 25623055 | Detail |
0.007 | pancreatic carcinoma | Further analysis showed that Cyr61 seemed to activate phosphatidylinositol 3-kin... | BeFree | 25104090 | Detail |
0.007 | pancreatic carcinoma | Recent data identify 3-phosphoinositide-dependent protein kinase 1 as a key tumo... | BeFree | 25152578 | Detail |
0.007 | pancreatic carcinoma | Activation of phosphoinositide-3 kinase (PI3K)-AKT-mammalian target of rapamycin... | BeFree | 25285629 | Detail |
0.007 | pancreatic carcinoma | Taken together, these data indicate that inhibition of MEK and PI3K alone or in ... | BeFree | 25376606 | Detail |
0.002 | Gastrointestinal Stromal Tumors | microRNA-218 increase the sensitivity of gastrointestinal stromal tumor to imati... | BeFree | 24706111 | Detail |
0.002 | Gastrointestinal Stromal Tumors | We tested the in vivo efficacy of three PI3K inhibitors (PI3Ki) in patient-deriv... | BeFree | 25316817 | Detail |
<0.001 | Cancer of Nasopharynx | NA | BeFree | Detail | |
0.002 | Anaplastic thyroid carcinoma | Here, we outlined the common pathways that are altered in ATC, including the BRA... | BeFree | 25347569 | Detail |
<0.001 | Medullary carcinoma of thyroid | PI3K/Akt/mTOR: A promising therapeutic target for non-medullary thyroid carcinom... | BeFree | 26138515 | Detail |
0.002 | Papillary thyroid carcinoma | NA | BeFree | Detail | |
0.009 | Malignant neoplasm of lung | RNA interference-mediated knockdown of RhoGDI2 induces the migration and invasio... | BeFree | 25266803 | Detail |
0.009 | Malignant neoplasm of lung | Common molecular drivers of lung cancer are mutations in receptor tyrosine kinas... | BeFree | 25524703 | Detail |
0.009 | Malignant neoplasm of lung | When the chimeric ubiquitin ligases were introduced into lung cancer SPC-A1 cell... | BeFree | 25573345 | Detail |
0.009 | Malignant neoplasm of lung | The altered PI3K/mTOR pathway is implicated in lung cancer, but mTOR inhibitors ... | BeFree | 25673697 | Detail |
0.009 | Malignant neoplasm of lung | It was found that AKT1 and PI3K/p85 expression was upregulated in LCSCs compared... | BeFree | 25738369 | Detail |
0.009 | Malignant neoplasm of lung | Hepatocyte growth factor (HGF) induces resistance to reversible and irreversible... | BeFree | 26063323 | Detail |
<0.001 | age related macular degeneration | NA | BeFree | Detail | |
<0.001 | Systemic Inflammatory Response Syndrome | NA | BeFree | Detail | |
<0.001 | Sepsis | NA | BeFree | Detail | |
<0.001 | Carcinoma, Small Cell | NA | BeFree | Detail | |
<0.001 | Bannayan-Riley-Ruvalcaba syndrome | NA | BeFree | Detail | |
<0.001 | polymicrogyria | NA | BeFree | Detail | |
0.003 | Impaired glucose tolerance | NA | BeFree,GAD | Detail | |
<0.001 | Virchow's node (disorder) | Genome-wide analyses have identified four major signaling nodes that are most fr... | BeFree | 25070358 | Detail |
<0.001 | Familial Alzheimer Disease (FAD) | NA | BeFree | Detail | |
<0.001 | Stage II Colon Cancer | NA | BeFree | Detail | |
0.002 | Carcinoma breast stage IV | Here, resistance to a class I PI3K inhibitor in a model of metastatic breast can... | BeFree | 26058079 | Detail |
<0.001 | inflammatory breast carcinoma | Molecular aberrations affecting the PI3K pathway may play a role in the progress... | BeFree | 24634376 | Detail |
<0.001 | Stage IV Bladder Cancer AJCC v6 | NA | BeFree | Detail | |
<0.001 | Prostate cancer recurrent | Activation of the PI3K/AKT signal pathway is a known driving force for the progr... | BeFree | 24983969 | Detail |
<0.001 | Metastatic melanoma | Macrophage migration inhibitory factor engages PI3K/Akt signalling and is a prog... | BeFree | 25168062 | Detail |
<0.001 | Cancer of Head and Neck | NA | BeFree | Detail | |
<0.001 | Liver and Intrahepatic Biliary Tract Carcinoma | NA | BeFree | Detail | |
<0.001 | B-cell adult acute lymphoblastic leukemia | Our studies indicate that CK2-mediated PTEN posttranslational inactivation, asso... | BeFree | 24561792 | Detail |
0.001 | Squamous cell carcinoma of esophagus | Disruption of the PTEN/PI3K pathway involved in TGF-β1-induced EMT may provide p... | BeFree | 25175594 | Detail |
0.001 | Squamous cell carcinoma of esophagus | Notably, high activity of hedgehog signaling and the PI3K pathway in approximate... | BeFree | 25839328 | Detail |
0.001 | Squamous cell carcinoma of esophagus | Dasatinib enhances cisplatin sensitivity in human esophageal squamous cell carci... | BeFree | 25843419 | Detail |
<0.001 | Adenocarcinoma Of Esophagus | ErbB2 signaling activates the Hedgehog pathway via PI3K-Akt in human esophageal ... | BeFree | 25435423 | Detail |
<0.001 | cervical squamous cell carcinoma | The objective of this study was to investigate the predictive value of common ge... | BeFree | 25773678 | Detail |
0.001 | Conventional (Clear Cell) Renal Cell Carcinoma | Loss of MLH1 confers resistance to PI3Kβ inhibitors in renal clear cell carcinom... | BeFree | 25528216 | Detail |
0.001 | Conventional (Clear Cell) Renal Cell Carcinoma | We identified the selective PI3Kβ inhibitor TGX221 as a selective inhibitor for ... | BeFree | 25853938 | Detail |
0.001 | Conventional (Clear Cell) Renal Cell Carcinoma | High selectivity of PI3Kβ inhibitors in SETD2-mutated renal clear cell carcinoma... | BeFree | 26537074 | Detail |
0.003 | Solid tumour | First-in-human phase I study of pictilisib (GDC-0941), a potent pan-class I phos... | BeFree | 25370471 | Detail |
0.003 | Solid tumour | BYL719, which selectively inhibits the alpha isoform of the phosphatidylinositol... | BeFree | 25544637 | Detail |
<0.001 | Adenocarcinoma of pancreas | NA | BeFree | Detail | |
<0.001 | Prostatic Intraepithelial Neoplasias | NA | BeFree | Detail | |
0.003 | cervix carcinoma | Taken together, our data suggest that anti-VEGFa treatment in cervical cancer ma... | BeFree | 25135429 | Detail |
0.003 | cervix carcinoma | CD38 is highly expressed and affects the PI3K/Akt signaling pathway in cervical ... | BeFree | 25310288 | Detail |
0.003 | cervix carcinoma | Peroxisome proliferator-activated receptor-gamma agonist 4-O-methylhonokiol indu... | BeFree | 25563418 | Detail |
0.003 | cervix carcinoma | The phosphatase and tensin homolog deleted on chromosome 10 (PTEN) protein is pr... | BeFree | 25738254 | Detail |
0.003 | cervix carcinoma | Butein suppresses cervical cancer growth through the PI3K/AKT/mTOR pathway. | BeFree | 25962638 | Detail |
<0.001 | Carcinoid tumor no ICD-O subtype | NA | BeFree | Detail | |
<0.001 | Ceruminous adenoma | NA | BeFree | Detail | |
<0.001 | Round cell liposarcoma | NA | BeFree | Detail | |
<0.001 | anaplastic astrocytoma | NA | BeFree | Detail | |
<0.001 | pilocytic astrocytoma | NA | BeFree | Detail | |
0.003 | Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse | NA | BeFree | Detail | |
<0.001 | Adenocarcinoma of colon | In this study, the inhibitory effect of KYNA on activation of phosphoinositide 3... | BeFree | 25012123 | Detail |
<0.001 | Impaired cognition | NA | BeFree | Detail | |
<0.001 | Malignant neoplasm of liver | NA | BeFree | Detail | |
<0.001 | malignant mesothelioma | NA | BeFree | Detail | |
0.007 | Malignant neoplasm of pancreas | Recent data identify 3-phosphoinositide-dependent protein kinase 1 as a key tumo... | BeFree | 25152578 | Detail |
0.007 | Malignant neoplasm of pancreas | Activation of phosphoinositide-3 kinase (PI3K)-AKT-mammalian target of rapamycin... | BeFree | 25285629 | Detail |
0.007 | Malignant neoplasm of pancreas | Taken together, these data indicate that inhibition of MEK and PI3K alone or in ... | BeFree | 25376606 | Detail |
<0.001 | Disseminated Malignant Neoplasm | First-in-human study of CH5132799, an oral class I PI3K inhibitor, studying toxi... | BeFree | 25231405 | Detail |
<0.001 | juvenile myelomonocytic leukemia | Juvenile myelomonocytic leukaemia-associated mutation in Cbl promotes resistance... | BeFree | 24469048 | Detail |
0.017 | Malignant neoplasm of prostate | We identified differential therapeutic vulnerabilities that emerge upon the loss... | BeFree | 24866151 | Detail |
0.017 | Malignant neoplasm of prostate | A genome-wide RNAi screen identifies FOXO4 as a metastasis-suppressor through co... | BeFree | 24983969 | Detail |
0.017 | Malignant neoplasm of prostate | The impact of miRNA on the canonical TGF-β Smad signalling pathway has been well... | BeFree | 24985060 | Detail |
0.017 | Malignant neoplasm of prostate | Restoration of PTEN expression or inhibition of PI3K action decreased cPLA₂α exp... | BeFree | 25026288 | Detail |
0.017 | Malignant neoplasm of prostate | Genome-wide analyses have identified four major signaling nodes that are most fr... | BeFree | 25070358 | Detail |
0.017 | Malignant neoplasm of prostate | Targeting the PI3K/Akt pathway in prostate cancer: challenges and opportunities ... | BeFree | 25120209 | Detail |
0.017 | Malignant neoplasm of prostate | The findings from this study suggest that the combination of dual PI3K/Akt/mTOR ... | BeFree | 25275598 | Detail |
0.017 | Malignant neoplasm of prostate | Co-targeting AR and PI3K/AKT signaling has been proposed to be a more effective ... | BeFree | 25360799 | Detail |
0.017 | Malignant neoplasm of prostate | The Upregulation of PI3K/Akt and MAP Kinase Pathways is Associated with Resistan... | BeFree | 25640606 | Detail |
0.017 | Malignant neoplasm of prostate | Among the cancer networks and STNs we considered, it is found that there is a su... | BeFree | 25707690 | Detail |
0.001 | Hematologic Neoplasms | NA | BeFree | Detail | |
<0.001 | Chorea Acanthocytosis Syndrome | NA | BeFree | Detail | |
<0.001 | Lymphatic Abnormalities | The activation of a central growth/survival pathway (PI3K/AKT) represents a feas... | BeFree | 25292196 | Detail |
<0.001 | Hemimegalencephaly | NA | BeFree | Detail | |
<0.001 | Endometrioid tumor | Endometrial cancers have been recently molecularly characterized; amplifications... | BeFree | 24820961 | Detail |
0.012 | endometrial carcinoma | The impact of microRNA-mediated PI3K/AKT signaling on epithelial-mesenchymal tra... | BeFree | 25141911 | Detail |
0.012 | endometrial carcinoma | This article reviews the results of Phase II clinical trials of PI3K/Akt/mTOR pa... | BeFree | 25301678 | Detail |
0.012 | endometrial carcinoma | The phosphoinositol-3 kinase (PI3K) pathway is frequently dysregulated in endome... | BeFree | 25624430 | Detail |
0.012 | endometrial carcinoma | PIKing the type and pattern of PI3K pathway mutations in endometrioid endometria... | BeFree | 25701704 | Detail |
0.012 | endometrial carcinoma | NEDD4 ubiquitin ligase is a putative oncogene in endometrial cancer that activat... | BeFree | 26193427 | Detail |
<0.001 | Secondary malignant neoplasm of liver | NA | BeFree | Detail | |
<0.001 | dementia | NA | BeFree | Detail | |
<0.001 | Recurrent tumor | Other molecular alterations, like mTOR or PI3K pathway deregulation, or Matrilin... | BeFree | 24554201 | Detail |
<0.001 | Increased drug resistance | NA | BeFree | Detail | |
<0.001 | Metabolic syndrome X | NA | BeFree | Detail | |
<0.001 | Neurodegenerative Disorders | NA | BeFree | Detail | |
<0.001 | Mood Disorders | NA | BeFree | Detail | |
<0.001 | Myxoid/Round Cell Liposarcoma | NA | BeFree | Detail | |
0.003 | Malignant neoplasm of esophagus | Therefore, concomitant blockage of the ErbB2-PI3K pathway and the Hedgehog downs... | BeFree,GAD | 25435423 | Detail |
0.007 | Thyroid carcinoma | The present review focuses on the most recent developments on the role of the PI... | BeFree | 26138515 | Detail |
0.001 | Ewings sarcoma | We further show that expression of PTEN, a well-established, potent tumor suppre... | BeFree | 25603314 | Detail |
<0.001 | Squamous cell carcinoma of skin | Y-box Binding Protein-1 Is Part of a Complex Molecular Network Linking ΔNp63α to... | BeFree | 25639555 | Detail |
<0.001 | Malignant glioma | NA | BeFree | Detail | |
<0.001 | Tonsillar Carcinoma | Divergence of P53, PTEN, PI3K, Akt and mTOR expression in tonsillar cancer. | BeFree | 24616007 | Detail |
<0.001 | Infected ascites | NA | BeFree | Detail | |
0.003 | Osteosarcoma of bone | Knockdown of CXCR7 suppressed proliferation and invasion of OS cells through dec... | BeFree | 24969680 | Detail |
0.003 | Osteosarcoma of bone | The present results indicated that LY294002 inhibits the malignant phenotype of ... | BeFree | 25351625 | Detail |
0.003 | Osteosarcoma of bone | Complementary genomic approaches highlight the PI3K/mTOR pathway as a common vul... | BeFree | 25512523 | Detail |
0.003 | Osteosarcoma of bone | In conclusion, icariin possesses a reversal effect on multidrug resistance in MG... | BeFree | 25747987 | Detail |
<0.001 | Costello syndrome (disorder) | Costello syndrome (CS) is a rare genetic disorder caused, in the majority of cas... | BeFree | 25367099 | Detail |
<0.001 | Carcinoma of larynx | NA | BeFree | Detail | |
0.035 | Carcinogenesis | When combined with previous studies, our data suggest that dual induction of PAR... | BeFree | 24469043 | Detail |
0.035 | Carcinogenesis | The phosphatidylinositol 3-kinase (PI3K), MAP kinase (MAPK), and related pathway... | BeFree | 24700299 | Detail |
0.035 | Carcinogenesis | R-Ras2 drives tumorigenesis in a phosphatidylinostiol-3 kinase (PI3K)-dependent ... | BeFree | 24826867 | Detail |
0.035 | Carcinogenesis | We further show that superactivation of the prosurvival PI3K-AKT signaling pathw... | BeFree | 24866151 | Detail |
0.035 | Carcinogenesis | These findings further suggest that regulation of SUMOylation by PI3K/Akt signal... | BeFree | 24954506 | Detail |
0.035 | Carcinogenesis | The findings indicate that epigenetic inactivation of INPP4B is one of the key m... | BeFree | 25126743 | Detail |
0.035 | Carcinogenesis | Furthermore, miR-200a induces cell transformation and tumorigenesis in immunocom... | BeFree | 25239643 | Detail |
0.035 | Carcinogenesis | We here demonstrate that PIK3CA mutations, PTEN loss, PI3K and KRAS activation a... | BeFree | 25415225 | Detail |
0.035 | Carcinogenesis | Phosphatidylinositol 3-kinases (PI3Ks) play important roles in human tumorigenes... | BeFree | 25622909 | Detail |
0.035 | Carcinogenesis | Given the contribution of HRG signaling and the PI3K-Akt pathway in particular t... | BeFree | 25630670 | Detail |
0.035 | Carcinogenesis | The PI3K/Akt and MAP kinase pathways play important roles in a variety of normal... | BeFree | 25640606 | Detail |
0.035 | Carcinogenesis | Single nucleotide polymorphisms (SNPs) in the PI3K/PTEN/AKT/mTOR signaling pathw... | BeFree | 25654238 | Detail |
0.035 | Carcinogenesis | Pathways known to affect tumorigenesis across a wide spectrum of tissues are dys... | BeFree | 25726356 | Detail |
0.035 | Carcinogenesis | The phosphoinositide 3-kinase (PI3K)/Akt signaling pathway appears to be a key r... | BeFree | 25738254 | Detail |
0.035 | Carcinogenesis | Our findings support the de-regulation of the PI3K/Akt/mTOR and MAPK signaling p... | BeFree | 25862896 | Detail |
0.002 | Leukemogenesis | NA | BeFree | Detail | |
<0.001 | Tumor Initiation | NA | BeFree | Detail | |
0.017 | prostate carcinoma | We identified differential therapeutic vulnerabilities that emerge upon the loss... | BeFree | 24866151 | Detail |
0.017 | prostate carcinoma | A genome-wide RNAi screen identifies FOXO4 as a metastasis-suppressor through co... | BeFree | 24983969 | Detail |
0.017 | prostate carcinoma | The impact of miRNA on the canonical TGF-β Smad signalling pathway has been well... | BeFree | 24985060 | Detail |
0.017 | prostate carcinoma | Restoration of PTEN expression or inhibition of PI3K action decreased cPLA₂α exp... | BeFree | 25026288 | Detail |
0.017 | prostate carcinoma | Genome-wide analyses have identified four major signaling nodes that are most fr... | BeFree | 25070358 | Detail |
0.017 | prostate carcinoma | Targeting the PI3K/Akt pathway in prostate cancer: challenges and opportunities ... | BeFree | 25120209 | Detail |
0.017 | prostate carcinoma | The findings from this study suggest that the combination of dual PI3K/Akt/mTOR ... | BeFree | 25275598 | Detail |
0.017 | prostate carcinoma | Co-targeting AR and PI3K/AKT signaling has been proposed to be a more effective ... | BeFree | 25360799 | Detail |
0.017 | prostate carcinoma | The Upregulation of PI3K/Akt and MAP Kinase Pathways is Associated with Resistan... | BeFree | 25640606 | Detail |
0.017 | prostate carcinoma | Among the cancer networks and STNs we considered, it is found that there is a su... | BeFree | 25707690 | Detail |
0.004 | Epithelial ovarian cancer | Inhibiting the PI3K/AKT pathway may be a useful treatment for ovarian carcinoma. | BeFree | 25216292 | Detail |
0.004 | Epithelial ovarian cancer | In conclusion, the results of the present study demonstrated that PI3K/AKT and R... | BeFree | 25405658 | Detail |
0.004 | Epithelial ovarian cancer | These findings revealed that miR‑338‑3p may act as a tumor suppressor that block... | BeFree | 25776272 | Detail |
<0.001 | invasive cancer | Therefore, the hyperactivity of PI3K/Akt pathway and elevated levels of p53R2 ca... | BeFree | 25086499 | Detail |
<0.001 | Refractory cancer | NA | BeFree | Detail | |
0.043 | breast carcinoma | Direct inhibition of PI3K in combination with dual HER2 inhibitors is required f... | BeFree | 24451154 | Detail |
0.043 | breast carcinoma | Characterization of breast cancers with PI3K mutations in an academic practice s... | BeFree | 24722917 | Detail |
0.043 | breast carcinoma | Their prognostic value and that of the phosphatidylinositol 3-kinase (PI3K) path... | BeFree | 24981670 | Detail |
0.043 | breast carcinoma | Phosphatidylinositol 3-kinase (PI3K) pathway deregulation (that is PIK3CA mutati... | BeFree | 25056500 | Detail |
0.043 | breast carcinoma | Western blot analysis data indicate that MAPK/ERK and PI3K/Akt signaling in brea... | BeFree | 25127034 | Detail |
0.043 | breast carcinoma | Microarray phosphatome profiling of breast cancer patients unveils a complex pho... | BeFree | 25201346 | Detail |
0.043 | breast carcinoma | In the present study, we have shown for the first time that HBA decreased the ex... | BeFree | 25299784 | Detail |
0.043 | breast carcinoma | Axl as a downstream effector of TGF-β1 via PI3K/Akt-PAK1 signaling pathway promo... | BeFree | 25327287 | Detail |
0.043 | breast carcinoma | Regulation of the cell cycle and PI3K/Akt/mTOR signaling pathway by tanshinone I... | BeFree | 25355053 | Detail |
0.043 | breast carcinoma | LYN(D189Y) overexpression abrogated growth inhibition by fulvestrant and/or the ... | BeFree | 25401474 | Detail |
0.043 | breast carcinoma | Phosphatidylinositol-3-kinase (PI3K)/AKT pathway mutations are associated with c... | BeFree | 25422220 | Detail |
0.043 | breast carcinoma | The PI3K/mTOR dual inhibitor P7170 demonstrates potent activity against endocrin... | BeFree | 25491778 | Detail |
0.043 | breast carcinoma | In conclusion, activating the PI3K pathway is associated with low pCR to trastuz... | BeFree | 25542038 | Detail |
0.043 | breast carcinoma | Estrogen-responsive genes most significantly influenced by cohesin were enriched... | BeFree | 25542856 | Detail |
0.043 | breast carcinoma | BYL719, which selectively inhibits the alpha isoform of the phosphatidylinositol... | BeFree | 25544637 | Detail |
0.043 | breast carcinoma | We investigated whether mutations in the gene encoding the phosphatidylinositol ... | BeFree | 25559818 | Detail |
0.043 | breast carcinoma | In the present study, we demonstrate that PI3K pathway regulates phenotypic chan... | BeFree | 25643809 | Detail |
0.043 | breast carcinoma | Further, PI3K is thought to be the main driver of lapatinib resistance, but our ... | BeFree | 25692408 | Detail |
0.043 | breast carcinoma | The epidermal growth factor receptor (EGFR)/PI3K/AKT signaling pathway aberratio... | BeFree | 25702787 | Detail |
0.043 | breast carcinoma | In the present study, the protein expression levels of SET, protein phosphatase ... | BeFree | 25760096 | Detail |
0.043 | breast carcinoma | PI3K inhibition results in enhanced estrogen receptor function and dependence in... | BeFree | 25877889 | Detail |
0.043 | breast carcinoma | IL-8/PI3K/Akt/NF-κB/integrin β3 axis may be exploited for therapeutic interventi... | BeFree | 25979232 | Detail |
0.043 | breast carcinoma | Beyond ER and HER2, BRCA and PIK3CA mutations (when targeted with alpha-specific... | BeFree | 25993174 | Detail |
0.043 | breast carcinoma | Taken together, the prostacyclin/IP/PI3K-p38 MAPK axis has emerged as a novel pr... | BeFree | 26067757 | Detail |
0.043 | breast carcinoma | Resistance to trastuzumab in patients with HER2-overexpressing breast cancer is ... | BeFree | 26247526 | Detail |
0.043 | breast carcinoma | Collectively, our findings identify PIPP as a suppressor of oncogenic PI3K/AKT s... | BeFree | 26267533 | Detail |
0.043 | breast carcinoma | Inhibition of Autophagy Increases Proliferation Inhibition and Apoptosis Induced... | BeFree | 26427150 | Detail |
0.008 | Carcinoma of lung | RNA interference-mediated knockdown of RhoGDI2 induces the migration and invasio... | BeFree | 25266803 | Detail |
0.008 | Carcinoma of lung | Common molecular drivers of lung cancer are mutations in receptor tyrosine kinas... | BeFree | 25524703 | Detail |
0.008 | Carcinoma of lung | When the chimeric ubiquitin ligases were introduced into lung cancer SPC-A1 cell... | BeFree | 25573345 | Detail |
0.008 | Carcinoma of lung | The altered PI3K/mTOR pathway is implicated in lung cancer, but mTOR inhibitors ... | BeFree | 25673697 | Detail |
0.008 | Carcinoma of lung | It was found that AKT1 and PI3K/p85 expression was upregulated in LCSCs compared... | BeFree | 25738369 | Detail |
0.008 | Carcinoma of lung | Hepatocyte growth factor (HGF) induces resistance to reversible and irreversible... | BeFree | 26063323 | Detail |
<0.001 | Secondary malignant neoplasm of lymph node | Our data showed that the PTEN/PI3K pathway was active in human ESCC tissues in v... | BeFree | 25175594 | Detail |
0.007 | colon carcinoma | Synergism of PI3K/Akt inhibition and Fas activation on colon cancer cell death. | BeFree | 25199763 | Detail |
0.007 | colon carcinoma | Quinazoline based small molecule exerts potent tumour suppressive properties by ... | BeFree | 25554016 | Detail |
0.007 | colon carcinoma | In the present study, the expression status of miR-218 and the role of the phosp... | BeFree | 25760926 | Detail |
0.007 | colon carcinoma | Combined ginger extract & Gelam honey modulate Ras/ERK and PI3K/AKT pathway gene... | BeFree | 25889965 | Detail |
0.007 | colon carcinoma | Here, we detected its effects on DLD-1 and SW480 (two human colon cancer cell li... | BeFree | 26225471 | Detail |
0.011 | stomach carcinoma | These data suggest that EGF-induced activation of MMP7 and MMP13 in GC is throug... | BeFree | 25085584 | Detail |
0.011 | stomach carcinoma | In conclusion, knockdown of the c‑Met gene promoted gastric cancer cell apoptosi... | BeFree | 25395073 | Detail |
0.011 | stomach carcinoma | Mechanically, PTP1B promotes gastric cancer cell proliferation, survival and inv... | BeFree | 25590580 | Detail |
0.011 | stomach carcinoma | Therefore, our studies reveal for the first time that inhibition of the PI3K-Akt... | BeFree | 25640278 | Detail |
0.011 | stomach carcinoma | Hepatocyte growth factor (HGF) upregulates heparanase expression via the PI3K/Ak... | BeFree | 25727320 | Detail |
0.003 | Carcinoma of bladder | These findings may have high relevance in terms of using PI3K-targeted therapies... | BeFree | 24347284 | Detail |
0.003 | Carcinoma of bladder | Targeting the genetic alterations of the PI3K-AKT-mTOR pathway: its potential us... | BeFree | 24929024 | Detail |
0.003 | Carcinoma of bladder | Our findings suggest that miR-21 acts as a molecular switch to regulate aerobic ... | BeFree | 25266796 | Detail |
0.003 | Carcinoma of bladder | Taken together, EN2 may be a candidate oncogene in BC by activating the PI3K/Akt... | BeFree | 25812440 | Detail |
<0.001 | Malignant Female Reproductive System Neoplasm | This article reviews the results of Phase II clinical trials of PI3K/Akt/mTOR pa... | BeFree | 25301678 | Detail |
<0.001 | skin carcinoma | NA | BeFree | Detail | |
0.005 | Central neuroblastoma | Moreover, inhibitors of PI3K/mTOR and GLI signaling reduced neuroblastoma cell g... | BeFree | 25134527 | Detail |
0.005 | Central neuroblastoma | Molecular rationale for the use of PI3K/AKT/mTOR pathway inhibitors in combinati... | BeFree | 25228590 | Detail |
0.005 | Central neuroblastoma | We previously demonstrated that PI3K Class IIβ (PI3KC2β) and its regulator inter... | BeFree | 25622909 | Detail |
<0.001 | Malignant neoplasm of kidney | NA | BeFree | Detail | |
<0.001 | biliary tract cancer | Targeted inhibition of the PI3K/mTOR and Hhpathways indicates a new avenue for B... | BeFree | 25742482 | Detail |
<0.001 | Malignant neoplasm tonsil | Divergence of P53, PTEN, PI3K, Akt and mTOR expression in tonsillar cancer. | BeFree | 24616007 | Detail |
<0.001 | Malignant Squamous Cell Neoplasm | NA | BeFree | Detail | |
0.001 | malignant pleural mesothelioma | MET and PI3K/mTOR as a potential combinatorial therapeutic target in malignant p... | BeFree | 25221930 | Detail |
<0.001 | Metastatic Endometrial Carcinoma | NA | BeFree | Detail | |
<0.001 | Heartburn acidity | NA | BeFree | Detail | |
<0.001 | Helicobacter pylori infection | Inhibition of PI3K and Akt kinase prevented the phosphorylation of 4E-BP1, sugge... | BeFree | 25194338 | Detail |
<0.001 | Invasive breast carcinoma | PI3K pathway activation in high-grade ductal carcinoma in situ--implications for... | BeFree | 24634376 | Detail |
0.002 | Rhabdoid Tumor of the Kidney | Our model allowed us to test the contributions of oncogenes in the RTK/RAS/PI(3)... | BeFree | 24752661 | Detail |
<0.001 | Diffuse large B-cell lymphoma recurrent | NA | BeFree | Detail | |
<0.001 | Philadelphia chromosome positive | NA | BeFree | Detail | |
<0.001 | dedifferentiated chondrosarcoma | NA | BeFree | Detail | |
<0.001 | latent infection | NA | BeFree | Detail | |
<0.001 | Advanced cancer | NA | BeFree | Detail | |
<0.001 | Erdheim-Chester disease | NA | BeFree | Detail | |
<0.001 | SHORT syndrome | NA | BeFree | Detail | |
<0.001 | Cerebral Ischemia | NA | BeFree | Detail | |
<0.001 | ovarian neoplasm | NA | BeFree | Detail | |
<0.001 | Metastatic Prostate Carcinoma | NA | BeFree | Detail | |
<0.001 | Colorectal cancer metastatic | NA | BeFree | Detail | |
<0.001 | Drug Resistant Epilepsy | In this study we performed multiplex targeted sequencing of 10 genes in the PI3K... | BeFree | 25722288 | Detail |
0.013 | Malignant neoplasm of ovary | Re-expression of ARHI in ovarian cancer cells blocks signaling through the PI3K ... | BeFree | 24769729 | Detail |
0.013 | Malignant neoplasm of ovary | MicroRNA-497 suppresses angiogenesis by targeting vascular endothelial growth fa... | BeFree | 25176450 | Detail |
0.013 | Malignant neoplasm of ovary | Moreover, LY294002, a potent and specific cell-permeable inhibitor of phosphatid... | BeFree | 25340291 | Detail |
0.013 | Malignant neoplasm of ovary | The PI3K/AKT/mTOR pathway as a therapeutic target in ovarian cancer. | BeFree | 25677064 | Detail |
<0.001 | High-Grade Prostatic Intraepithelial Neoplasia | NA | BeFree | Detail | |
0.005 | Squamous cell carcinoma of the head and neck | A comprehensive evaluation of biomarkers predictive of response to PI3K inhibito... | BeFree | 25193510 | Detail |
0.005 | Squamous cell carcinoma of the head and neck | Additional study is required to develop new model systems and approaches to dete... | BeFree | 25855885 | Detail |
<0.001 | Mammary Carcinoma, Human | NA | BeFree | Detail | |
<0.001 | Morphologically altered structure | NA | BeFree | Detail | |
<0.001 | sarcoma | NA | BeFree | Detail | |
<0.001 | attention deficit hyperactivity disorder | NA | BeFree | Detail | |
<0.001 | Enterochromaffin-like cell carcinoid | NA | BeFree | Detail | |
<0.001 | Atypical teratoid/rhabdoid tumor | NA | BeFree | Detail | |
<0.001 | Chronic myeloproliferative disorder | Herein, we will review the clinically relevant inhibitors of the PI3K pathway th... | BeFree | 26062813 | Detail |
<0.001 | Pancreatic intraepithelial neoplasia | NA | BeFree | Detail | |
<0.001 | Salivary duct carcinoma | NA | BeFree | Detail | |
<0.001 | Sendai virus infection | Our results show that Sendai virus infection, which is recognized by RIG-I, led ... | BeFree | 25158146 | Detail |
<0.001 | Hormone refractory prostate cancer | NA | BeFree | Detail | |
<0.001 | Classical Hodgkin's Lymphoma | NA | BeFree | Detail | |
<0.001 | Epstein-Barr Virus-Related Lymphoma | NA | BeFree | Detail | |
<0.001 | External Auditory Canal Ceruminous Adenoma | NA | BeFree | Detail | |
<0.001 | Testicular Germ Cell Tumor | NA | BeFree | Detail | |
<0.001 | differentiated thyroid gland carcinoma | NA | BeFree | Detail | |
<0.001 | Granulosa cell tumor of the ovary | NA | BeFree | Detail | |
0.001 | renal carcinoma | Curcumin significantly enhances dual PI3K/Akt and mTOR inhibitor NVP-BEZ235-indu... | BeFree | 24743574 | Detail |
<0.001 | Metastatic Carcinoma | Targeted PI3K/AKT/mTOR therapy for metastatic carcinomas of the cervix: A phase ... | BeFree | 25426553 | Detail |
0.006 | Mammary Neoplasms | We validated the top ranking genes, i.e., PIK3CA and PIK3CB, by showing that the... | BeFree,LHGDN | 25195596 | Detail |
<0.001 | Angiogenic Switch | NA | BeFree | Detail | |
<0.001 | Hepatocarcinogenesis | NA | BeFree | Detail | |
0.001 | Cancer Cell Growth | NA | BeFree | Detail | |
0.002 | Tumor Angiogenesis | The tumor suppressor WIF1 was also found to be capable of suppressing tumor grow... | BeFree | 25086206 | Detail |
0.002 | Tumor Angiogenesis | Increased CYP4Z2P- and CYP4Z1-3'UTR expression promotes tumor angiogenesis in br... | BeFree | 25701119 | Detail |
<0.001 | Tumor Promotion | NA | BeFree | Detail | |
0.002 | Xenograft Model | The combination of HER2 inhibitors with PI3K inhibition was studied in HER2-ampl... | BeFree | 24451154 | Detail |
0.002 | Xenograft Model | Using AR + TNBC cell line and xenograft models we evaluated the effectiveness of... | BeFree | 25103565 | Detail |
0.002 | Xenograft Model | In addition, the phosphoinositide-3-kinase (PI3K)/Akt/mammalian target of rapamy... | BeFree | 25153728 | Detail |
0.002 | Xenograft Model | We tested the in vivo efficacy of three PI3K inhibitors (PI3Ki) in patient-deriv... | BeFree | 25316817 | Detail |
0.012 | colorectal cancer | The added predictive value of additional biomarkers in the RAS-RAF-MAPK and PI3K... | BeFree | 24666267 | Detail |
0.012 | colorectal cancer | The role of c2orf68 and PI3K/Akt/mTOR pathway in human colorectal cancer. | BeFree | 25023051 | Detail |
0.012 | colorectal cancer | These data indicate that the capacity of retinol to inhibit PI3K activity confer... | BeFree | 25356626 | Detail |
0.012 | colorectal cancer | We conclude that cPLA2α is required for sustaining AKT phosphorylation at Ser473... | BeFree | 25365190 | Detail |
0.012 | colorectal cancer | Inhibitors against KRAS signaling mediators, namely, PI3K (phosphatidylinositol ... | BeFree | 25389372 | Detail |
0.012 | colorectal cancer | PTEN inactivation by mutation or allelic loss also occurs in CRCs. miR‑135b was ... | BeFree | 25571954 | Detail |
0.012 | colorectal cancer | The role of the PI3K pathway in colorectal cancer. | BeFree | 25591826 | Detail |
0.012 | colorectal cancer | Mutations in the RAS and PI3K pathways are associated with metastatic location i... | BeFree | 25920435 | Detail |
0.012 | colorectal cancer | Eight of these genes were linked to the Wnt, Hippo, TGF-β, EGF receptor, or PI3K... | BeFree | 26056301 | Detail |
<0.001 | Rash and Dermatitis Adverse Event Associated with Chemoradiation | NA | BeFree | Detail | |
<0.001 | Adenocarcinoma, Endometrioid | Preclinical investigations have suggested that the PI3K/AKT/mTOR pathway is freq... | BeFree | 25677064 | Detail |
0.001 | Glioblastoma multiforme | Here, using specific inhibitors, we found that the activation of EGFR signaling ... | BeFree | 25431263 | Detail |
0.001 | Glioblastoma multiforme | The phosphoinositide 3-kinase (PI3K)/Akt/PTEN signaling pathway is deregulated i... | BeFree | 25501707 | Detail |
<0.001 | Cirrhosis | NA | BeFree | Detail | |
<0.001 | androgen independent prostate cancer | NA | BeFree | Detail | |
<0.001 | tumor vasculature | Important mechanisms we discuss include (1) improved DNA repair in normal, but n... | BeFree | 24436017 | Detail |
<0.001 | Idiopathic Pulmonary Fibrosis | NA | BeFree | Detail | |
<0.001 | Familial ependymoma | NA | BeFree | Detail | |
<0.001 | ECTRODACTYLY, ECTODERMAL DYSPLASIA, AND CLEFT LIP/PALATE SYNDROME 1 | Although the mutation rates and mutational signatures of MSS and MSI-H EECs were... | BeFree | 25701704 | Detail |
<0.001 | Prostate Cancer, Hereditary, 7 | NA | BeFree | Detail | |
<0.001 | Megalanecephaly Polymicrogyria-Polydactyly Hydrocephalus Syndrome | NA | BeFree | Detail | |
0.006 | uterine corpus cancer | The impact of microRNA-mediated PI3K/AKT signaling on epithelial-mesenchymal tra... | BeFree | 25141911 | Detail |
0.006 | uterine corpus cancer | This article reviews the results of Phase II clinical trials of PI3K/Akt/mTOR pa... | BeFree | 25301678 | Detail |
0.006 | uterine corpus cancer | The phosphoinositol-3 kinase (PI3K) pathway is frequently dysregulated in endome... | BeFree | 25624430 | Detail |
0.006 | uterine corpus cancer | NEDD4 ubiquitin ligase is a putative oncogene in endometrial cancer that activat... | BeFree | 26193427 | Detail |
<0.001 | PTEN hamartoma tumor syndrome | NA | BeFree | Detail | |
<0.001 | Philadelphia chromosome-positive acute lymphoblastic leukemia | NA | BeFree | Detail | |
0.004 | Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | In this review, we summarize the existing knowledge of the relevance of Notch1 a... | BeFree | 24819383 | Detail |
0.004 | Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | We also explored the molecular mechanism of FHL1C overexpression-induced apoptos... | BeFree | 24952875 | Detail |
0.004 | Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | High activation of the PI3K-AKT-mTOR pathway is characteristic for T-cell acute ... | BeFree | 25241901 | Detail |
0.002 | Precursor Cell Lymphoblastic Leukemia Lymphoma | NA | BeFree | Detail | |
<0.001 | Urothelial Carcinoma | NA | BeFree | Detail | |
0.014 | liver carcinoma | This mode of action for calycopterin in our study provides strong support that i... | BeFree | 25060910 | Detail |
0.014 | liver carcinoma | The PI3K/Akt/Snail-dependent pathway may mediate the pro-invasive and pro-metast... | BeFree | 25070581 | Detail |
0.014 | liver carcinoma | The inhibition of PI3K/Akt activation abolished epithelial-mesenchymal transitio... | BeFree | 25087096 | Detail |
0.014 | liver carcinoma | Bioinformatic method was applied to predict the binding of miR-218 on HoxA10, an... | BeFree | 25120782 | Detail |
0.014 | liver carcinoma | In clinical HCC samples, high expression of both CXCR2 and CXCL5 showed a signif... | BeFree | 25462858 | Detail |
0.014 | liver carcinoma | The purpose of this study was to determine the impact of sorafenib on PI3K/AKT/m... | BeFree | 25778319 | Detail |
0.014 | liver carcinoma | HBx induced AFP receptor expressed to activate PI3K/AKT signal to promote expres... | BeFree | 25943101 | Detail |
0.014 | liver carcinoma | Down-Regulated NRSN2 Promotes Cell Proliferation and Survival Through PI3K/Akt/m... | BeFree | 26055238 | Detail |
0.014 | liver carcinoma | Moreover, LIFR knockdown could activate phosphoinositide 3-kinase/V-akt Murine T... | BeFree | 26249360 | Detail |
<0.001 | Oropharyngeal Carcinoma | NA | BeFree | Detail | |
<0.001 | Allergic rhinitis (disorder) | NA | BeFree | Detail | |
<0.001 | Thrombotic Microangiopathies | NA | BeFree | Detail | |
<0.001 | Macroencephaly | NA | BeFree | Detail | |
<0.001 | Kashin-Beck Disease | Role of selenoprotein S (SEPS1) -105G>A polymorphisms and PI3K/Akt signaling pat... | BeFree | 25433273 | Detail |
<0.001 | Human Papillomavirus Positive Oropharyngeal Squamous Cell Carcinoma | NA | BeFree | Detail | |
<0.001 | Chronic ulcerative colitis | NA | BeFree | Detail | |
<0.001 | Benign symmetrical lipomatosis | NA | BeFree | Detail | |
0.003 | Nasopharyngeal carcinoma | Epigenetic inactivation of inositol polyphosphate 4-phosphatase B (INPP4B), a re... | BeFree | 25126743 | Detail |
0.003 | Nasopharyngeal carcinoma | The current study demonstrated that EphA2 mediates sensitivity to paclitaxel via... | BeFree | 25351620 | Detail |
<0.001 | aggressive cancer | NA | BeFree | Detail | |
<0.001 | Fetal Alcohol Spectrum Disorders | NA | BeFree | Detail | |
<0.001 | Overgrowth syndrome | Mutations in PIK3CA, the gene encoding the p110α catalytic subunit of PI3K, are ... | BeFree | 25550458 | Detail |
<0.001 | Stage II Colon Cancer AJCC v7 | NA | BeFree | Detail | |
<0.001 | Primary acquired melanosis | The PI3K/AKT/mTOR (PAM) signaling pathway controls key cellular responses, such ... | BeFree | 25601471 | Detail |
<0.001 | myelodysplastic syndrome | NA | BeFree | Detail | |
0.003 | Triple Negative Breast Neoplasms | Different targeted therapies may be necessary for TNBC that involves activation ... | BeFree | 25009009 | Detail |
0.003 | Triple Negative Breast Neoplasms | PIK3CA mutations in androgen receptor-positive triple negative breast cancer con... | BeFree | 25103565 | Detail |
0.003 | Triple Negative Breast Neoplasms | Mutational profiles in triple-negative breast cancer defined by ultradeep multig... | BeFree | 25296970 | Detail |
0.003 | Triple Negative Breast Neoplasms | β-TrCP1 degradation is a novel action mechanism of PI3K/mTOR inhibitors in tripl... | BeFree | 25721419 | Detail |
<0.001 | ESTROGEN RESISTANCE | Activation of the phosphatidylinositol-3-kinase (PI3K) and/or mitogen-activated ... | BeFree | 24447434 | Detail |
<0.001 | ESTROGEN RESISTANCE | Activation of the phosphatidylinositol 3-kinase (PI3K)/AKT/mTOR pathway has been... | BeFree | 25491778 | Detail |
<0.001 | Experimental Organism Basal Cell Carcinoma | NA | BeFree | Detail | |
<0.001 | Congenital Abnormality | Brain overgrowth in disorders of RTK-PI3K-AKT signaling: a mosaic of malformatio... | BeFree | 25432429 | Detail |
0.002 | adenocarcinoma | NA | BeFree | Detail | |
<0.001 | Primary myelofibrosis | NA | BeFree | Detail | |
<0.001 | Alcoholic Intoxication, Chronic | NA | BeFree | Detail | |
<0.001 | Alzheimer's disease | NA | BeFree | Detail | |
<0.001 | arteriosclerosis | NA | BeFree | Detail | |
0.002 | rheumatoid arthritis | Following stimulation with 10 nM insulin for 30 min, the stable overexpression o... | BeFree | 25760103 | Detail |
<0.001 | asthma | NA | BeFree | Detail | |
<0.001 | Astrocytoma | NA | BeFree | Detail | |
<0.001 | atherosclerosis | NA | BeFree | Detail | |
<0.001 | autistic disorder | NA | BeFree | Detail | |
<0.001 | Autoimmune Diseases | NA | BeFree | Detail | |
0.002 | Barrett esophagus | NA | GAD | Detail | |
0.004 | Malignant neoplasm of urinary bladder | These findings may have high relevance in terms of using PI3K-targeted therapies... | BeFree | 24347284 | Detail |
0.004 | Malignant neoplasm of urinary bladder | Targeting the genetic alterations of the PI3K-AKT-mTOR pathway: its potential us... | BeFree | 24929024 | Detail |
0.004 | Malignant neoplasm of urinary bladder | Our findings suggest that miR-21 acts as a molecular switch to regulate aerobic ... | BeFree | 25266796 | Detail |
0.004 | Malignant neoplasm of urinary bladder | Taken together, EN2 may be a candidate oncogene in BC by activating the PI3K/Akt... | BeFree | 25812440 | Detail |
0.001 | Brain Neoplasms | NA | BeFree | Detail | |
0.047 | Malignant neoplasm of breast | Direct inhibition of PI3K in combination with dual HER2 inhibitors is required f... | BeFree,GAD | 24451154 | Detail |
0.047 | Malignant neoplasm of breast | Characterization of breast cancers with PI3K mutations in an academic practice s... | BeFree,GAD | 24722917 | Detail |
0.047 | Malignant neoplasm of breast | Their prognostic value and that of the phosphatidylinositol 3-kinase (PI3K) path... | BeFree,GAD | 24981670 | Detail |
0.047 | Malignant neoplasm of breast | Phosphatidylinositol 3-kinase (PI3K) pathway deregulation (that is PIK3CA mutati... | BeFree,GAD | 25056500 | Detail |
0.047 | Malignant neoplasm of breast | Western blot analysis data indicate that MAPK/ERK and PI3K/Akt signaling in brea... | BeFree,GAD | 25127034 | Detail |
0.047 | Malignant neoplasm of breast | Microarray phosphatome profiling of breast cancer patients unveils a complex pho... | BeFree,GAD | 25201346 | Detail |
0.047 | Malignant neoplasm of breast | In the present study, we have shown for the first time that HBA decreased the ex... | BeFree,GAD | 25299784 | Detail |
0.047 | Malignant neoplasm of breast | Axl as a downstream effector of TGF-β1 via PI3K/Akt-PAK1 signaling pathway promo... | BeFree,GAD | 25327287 | Detail |
0.047 | Malignant neoplasm of breast | Regulation of the cell cycle and PI3K/Akt/mTOR signaling pathway by tanshinone I... | BeFree,GAD | 25355053 | Detail |
0.047 | Malignant neoplasm of breast | LYN(D189Y) overexpression abrogated growth inhibition by fulvestrant and/or the ... | BeFree,GAD | 25401474 | Detail |
0.047 | Malignant neoplasm of breast | Phosphatidylinositol-3-kinase (PI3K)/AKT pathway mutations are associated with c... | BeFree,GAD | 25422220 | Detail |
0.047 | Malignant neoplasm of breast | The PI3K/mTOR dual inhibitor P7170 demonstrates potent activity against endocrin... | BeFree,GAD | 25491778 | Detail |
0.047 | Malignant neoplasm of breast | In conclusion, activating the PI3K pathway is associated with low pCR to trastuz... | BeFree,GAD | 25542038 | Detail |
0.047 | Malignant neoplasm of breast | Estrogen-responsive genes most significantly influenced by cohesin were enriched... | BeFree,GAD | 25542856 | Detail |
0.047 | Malignant neoplasm of breast | BYL719, which selectively inhibits the alpha isoform of the phosphatidylinositol... | BeFree,GAD | 25544637 | Detail |
0.047 | Malignant neoplasm of breast | We investigated whether mutations in the gene encoding the phosphatidylinositol ... | BeFree,GAD | 25559818 | Detail |
0.047 | Malignant neoplasm of breast | In the present study, we demonstrate that PI3K pathway regulates phenotypic chan... | BeFree,GAD | 25643809 | Detail |
0.047 | Malignant neoplasm of breast | Further, PI3K is thought to be the main driver of lapatinib resistance, but our ... | BeFree,GAD | 25692408 | Detail |
0.047 | Malignant neoplasm of breast | The epidermal growth factor receptor (EGFR)/PI3K/AKT signaling pathway aberratio... | BeFree,GAD | 25702787 | Detail |
0.047 | Malignant neoplasm of breast | In the present study, the protein expression levels of SET, protein phosphatase ... | BeFree,GAD | 25760096 | Detail |
0.047 | Malignant neoplasm of breast | PI3K inhibition results in enhanced estrogen receptor function and dependence in... | BeFree,GAD | 25877889 | Detail |
0.047 | Malignant neoplasm of breast | IL-8/PI3K/Akt/NF-κB/integrin β3 axis may be exploited for therapeutic interventi... | BeFree,GAD | 25979232 | Detail |
0.047 | Malignant neoplasm of breast | Beyond ER and HER2, BRCA and PIK3CA mutations (when targeted with alpha-specific... | BeFree,GAD | 25993174 | Detail |
0.047 | Malignant neoplasm of breast | Taken together, the prostacyclin/IP/PI3K-p38 MAPK axis has emerged as a novel pr... | BeFree,GAD | 26067757 | Detail |
0.047 | Malignant neoplasm of breast | Resistance to trastuzumab in patients with HER2-overexpressing breast cancer is ... | BeFree,GAD | 26247526 | Detail |
0.047 | Malignant neoplasm of breast | Collectively, our findings identify PIPP as a suppressor of oncogenic PI3K/AKT s... | BeFree,GAD | 26267533 | Detail |
0.047 | Malignant neoplasm of breast | Inhibition of Autophagy Increases Proliferation Inhibition and Apoptosis Induced... | BeFree,GAD | 26427150 | Detail |
<0.001 | Burkitt lymphoma | NA | BeFree | Detail | |
<0.001 | Carcinoid Tumor | NA | BeFree | Detail | |
0.007 | Malignant tumor of colon | Synergism of PI3K/Akt inhibition and Fas activation on colon cancer cell death. | BeFree | 25199763 | Detail |
0.007 | Malignant tumor of colon | Quinazoline based small molecule exerts potent tumour suppressive properties by ... | BeFree | 25554016 | Detail |
0.007 | Malignant tumor of colon | In the present study, the expression status of miR-218 and the role of the phosp... | BeFree | 25760926 | Detail |
0.007 | Malignant tumor of colon | Combined ginger extract & Gelam honey modulate Ras/ERK and PI3K/AKT pathway gene... | BeFree | 25889965 | Detail |
0.007 | Malignant tumor of colon | Here, we detected its effects on DLD-1 and SW480 (two human colon cancer cell li... | BeFree | 26225471 | Detail |
0.006 | Malignant neoplasm of endometrium | The impact of microRNA-mediated PI3K/AKT signaling on epithelial-mesenchymal tra... | BeFree | 25141911 | Detail |
0.006 | Malignant neoplasm of endometrium | This article reviews the results of Phase II clinical trials of PI3K/Akt/mTOR pa... | BeFree | 25301678 | Detail |
0.006 | Malignant neoplasm of endometrium | The phosphoinositol-3 kinase (PI3K) pathway is frequently dysregulated in endome... | BeFree | 25624430 | Detail |
0.006 | Malignant neoplasm of endometrium | NEDD4 ubiquitin ligase is a putative oncogene in endometrial cancer that activat... | BeFree | 26193427 | Detail |
<0.001 | Rectal Carcinoma | The phosphatidylinositol 3-kinase (PI3K), MAP kinase (MAPK), and related pathway... | BeFree | 24700299 | Detail |
0.006 | Malignant neoplasm of thyroid | NA | BeFree | Detail | |
<0.001 | Noninfiltrating Intraductal Carcinoma | PI3K pathway activation in high-grade ductal carcinoma in situ--implications for... | BeFree | 24634376 | Detail |
<0.001 | Merkel cell carcinoma | NA | BeFree | Detail | |
0.012 | Non-small cell lung carcinoma | In conclusion, the positive feedback loop between NOX4 and PI3K/Akt signaling co... | BeFree | 24946933 | Detail |
0.012 | Non-small cell lung carcinoma | We have recently shown that Semaphorin 4B (SEMA4B) inhibits the invasion of non-... | BeFree | 25746385 | Detail |
0.012 | Non-small cell lung carcinoma | ILT4 drives B7-H3 expression via PI3K/AKT/mTOR signalling and ILT4/B7-H3 co-expr... | BeFree | 26149216 | Detail |
Annotation
Annotations
Descrption | Source | Links |
---|---|---|
Curcumin significantly enhances dual PI3K/Akt and mTOR inhibitor NVP-BEZ235-induced apoptosis in hum... | DisGeNET | Detail |
We genotyped 70 genes involved in the pathogenesis of renal-cell carcinoma (including the VHL/HIF/VE... | DisGeNET | Detail |
The phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT) pathway has been identified as an import... | DisGeNET | Detail |
PI3Kβ inhibitor TGX221 selectively inhibits renal cell carcinoma cells with both VHL and SETD2 mutat... | DisGeNET | Detail |
Taken together, our findings indicate that ghrelin can activate Snail function via the GHS-R-PI3K-Ak... | DisGeNET | Detail |
Importantly, the level of miR-508 correlates with poor survival and activated PI3K/Akt signalling in... | DisGeNET | Detail |
Moreover, blocking the whole PI3K-AKT-mTOR pathway with the PI3K/mTOR dual inhibitor BEZ235 also sho... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Taken together, our data suggest that anti-VEGFa treatment in cervical cancer may inhibit both tumor... | DisGeNET | Detail |
CD38 is highly expressed and affects the PI3K/Akt signaling pathway in cervical cancer. | DisGeNET | Detail |
Peroxisome proliferator-activated receptor-gamma agonist 4-O-methylhonokiol induces apoptosis by tri... | DisGeNET | Detail |
The phosphatase and tensin homolog deleted on chromosome 10 (PTEN) protein is principally involved i... | DisGeNET | Detail |
Butein suppresses cervical cancer growth through the PI3K/AKT/mTOR pathway. | DisGeNET | Detail |
In cells infected with the closely related chikungunya virus (CHIKV), the PI3K-Akt-mTOR pathway was ... | DisGeNET | Detail |
Stimulation of chondrosarcoma with CCL5 augmented PI3K and Akt phosphorylation, while PI3K and Akt i... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
In acute myeloid leukemia (AML), several signaling pathways such as the phosphatidylinositol-3-kinas... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
The added predictive value of additional biomarkers in the RAS-RAF-MAPK and PI3K-AKT-mTOR pathways i... | DisGeNET | Detail |
The role of c2orf68 and PI3K/Akt/mTOR pathway in human colorectal cancer. | DisGeNET | Detail |
These data indicate that the capacity of retinol to inhibit PI3K activity confers its ability to dec... | DisGeNET | Detail |
We conclude that cPLA2α is required for sustaining AKT phosphorylation at Ser473 and cell proliferat... | DisGeNET | Detail |
Inhibitors against KRAS signaling mediators, namely, PI3K (phosphatidylinositol 3-kinase) and mTOR (... | DisGeNET | Detail |
PTEN inactivation by mutation or allelic loss also occurs in CRCs. miR‑135b was reported to be upreg... | DisGeNET | Detail |
The role of the PI3K pathway in colorectal cancer. | DisGeNET | Detail |
Mutations in the RAS and PI3K pathways are associated with metastatic location in colorectal cancers... | DisGeNET | Detail |
Eight of these genes were linked to the Wnt, Hippo, TGF-β, EGF receptor, or PI3K pathways, all invol... | DisGeNET | Detail |
NA | DisGeNET | Detail |
bFGF regulates autophagy and ubiquitinated protein accumulation induced by myocardial ischemia/reper... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Effects of D-Pinitol on Insulin Resistance through the PI3K/Akt Signaling Pathway in Type 2 Diabetes... | DisGeNET | Detail |
Podocyte-specific genetic ablation of XBP1 or inducible expression of ATF6 in mice aggravates DN. sX... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Therefore, concomitant blockage of the ErbB2-PI3K pathway and the Hedgehog downstream mediator Gli-1... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Moreover, TRIM24 regulates the expression of DNA repair enzyme O(6)-methylguanine-DNA methyltransfer... | DisGeNET | Detail |
ABT-263 (Navitoclax), an orally available small-molecule Bcl-2 inhibitor, and GDC-0941, a PI3K inhib... | DisGeNET | Detail |
In this study, we used inhibitors to block specific signaling pathways, including JAK, PI3K/Akt, and... | DisGeNET | Detail |
Application of a specific extracellular-related kinase 1/2 (ERK1/2) inhibitor, but not application o... | DisGeNET | Detail |
However, due to the development of resistance mechanisms, kinase inhibition studies targeting the PI... | DisGeNET | Detail |
The EGFR and PI3K/mTORC1/2 pathways are frequently altered in glioblastoma (GBM), but pharmacologic ... | DisGeNET | Detail |
The activation of PI3K/Akt1 signaling pathway is involved in the proliferation of glioblastoma; howe... | DisGeNET | Detail |
Further analyses revealed that Cyr61 seemed to activate PI3K/Akt/mTor signaling pathway to increase ... | DisGeNET | Detail |
TRIM24 promotes glioma progression and enhances chemoresistance through activation of the PI3K/Akt s... | DisGeNET | Detail |
These results suggest that Liq treatment enhances glioma cell susceptibility to TMZ by inhibiting th... | DisGeNET | Detail |
Several studies have attempted to investigate the effects of combining the inhibition of both PI3K a... | DisGeNET | Detail |
The loss of MAGI3 expression in glioma may enhance the proliferation of glioma cells via downregulat... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
This article highlights recent progress in characterizing the molecular mechanisms of PI3K isoform-s... | DisGeNET | Detail |
This novel mechanism of Dlg1 subversion by adenovirus to dysregulate PI3K could be used by other pat... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
In this study, we examined the effect of Ginsenoside Rb1 (GRb1) on ischemia/reperfusion-induced auto... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
In the present study, we have shown for the first time that HBA decreased the expression of phosphot... | DisGeNET | Detail |
The PI3K/Akt signaling pathway is constitutively activated in various leukemias. | DisGeNET | Detail |
Altogether, these results underline the key role of PI3K/AKT pathway in the generation of the CLL pr... | DisGeNET | Detail |
The phosphoinositide-3-kinase (PI3K)-delta and gamma inhibitor, IPI-145 (Duvelisib), overcomes signa... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Importantly, emodin was demonstrated as a new inhibitor of PI3K/Akt in AML cells, even in primary AM... | DisGeNET | Detail |
Inhibiting rescue pathways could improve the therapeutic efficacy of PI3K-targeted therapies in AML. | DisGeNET | Detail |
In the primary AML sample, we investigated the cell responses to ex vivo stimulation with stem cell ... | DisGeNET | Detail |
The Ras/Raf/MAPK and PI3K/Akt/mTOR pathways are key signaling cascades involved in the regulation of... | DisGeNET | Detail |
NA | DisGeNET | Detail |
The fusion gene bcr-abl develops chronic myeloid leukemia (CML), and stimulates PI3K/Akt/mTOR signal... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
HBx induced AFP receptor expressed to activate PI3K/AKT signal to promote expression of Src in liver... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
In conclusion, knockdown of the c‑Met gene promoted gastric cancer cell apoptosis and inhibited down... | DisGeNET | Detail |
Mechanically, PTP1B promotes gastric cancer cell proliferation, survival and invasiveness through mo... | DisGeNET | Detail |
Therefore, our studies reveal for the first time that inhibition of the PI3K-Akt pathway is involved... | DisGeNET | Detail |
Hepatocyte growth factor (HGF) upregulates heparanase expression via the PI3K/Akt/NF-κB signaling pa... | DisGeNET | Detail |
NA | DisGeNET | Detail |
Targeting the PI3K/AKT/mTOR signaling pathway in medulloblastoma. | DisGeNET | Detail |
The impact of RNA interference (RNAi)-mediated silencing of PI3K isoforms p110α and p110δ on global ... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Recent attention has focused on the role of phosphatidylinositol 3-kinase (PI3K) in both immune and ... | DisGeNET | Detail |
Cancers like multiple myeloma (MM), which display elevated activity in key translation regulatory no... | DisGeNET | Detail |
Furthermore, our results demonstrated that the enforced expression of miR-145 in H929 cells profound... | DisGeNET | Detail |
Previously we showed that tetraspanin overexpression in MM cell lines attenuated mTOR and PI3K casca... | DisGeNET | Detail |
NA | DisGeNET | Detail |
In situ assessment of PI3K and PTEN alterations in mycosis fungoides: correlation with clinicopathol... | DisGeNET | Detail |
NA | DisGeNET | Detail |
Herein, we will review the clinically relevant inhibitors of the PI3K pathway that have been evaluat... | DisGeNET | Detail |
NA | DisGeNET | Detail |
Mechanistically, knockdown of FAP inactivated PTEN/PI3K/AKT and Ras-ERK and its downstream signaling... | DisGeNET | Detail |
IL-7 splicing variant IL-7δ5 induces EMT and metastasis of human breast cancer cell lines MCF-7 and ... | DisGeNET | Detail |
Molecular profiling of patient-matched brain and extracranial melanoma metastases implicates the PI3... | DisGeNET | Detail |
However, the mechanisms and specific functions of PI3K isoforms in tumor invasion and metastasis are... | DisGeNET | Detail |
NOX4 promotes non-small cell lung cancer cell proliferation and metastasis through positive feedback... | DisGeNET | Detail |
Yet, little is known concerning the role of the PI3K/Akt/Snail-dependent pathway in sorafenib‑induce... | DisGeNET | Detail |
First-in-human study of CH5132799, an oral class I PI3K inhibitor, studying toxicity, pharmacokineti... | DisGeNET | Detail |
Overexpression of ribonuclease inhibitor defines good prognosis and suppresses proliferation and met... | DisGeNET | Detail |
These data indicate that the capacity of retinol to inhibit PI3K activity confers its ability to dec... | DisGeNET | Detail |
These findings suggest that CEACAM6 enhances invasion and metastasis in GC by promoting EMT via the ... | DisGeNET | Detail |
These findings indicated that MALAT1 might suppress the tumor growth and metastasis via PI3K/AKT sig... | DisGeNET | Detail |
In conclusion, this study suggested that EMT process can be triggered by the BMP2/BMPR axis in gastr... | DisGeNET | Detail |
The EGFR/PI3K/PTEN/Akt/mTORC pathway plays prominent roles in malignant transformation, prevention o... | DisGeNET | Detail |
SPOCK1 as a potential cancer prognostic marker promotes the proliferation and metastasis of gallblad... | DisGeNET | Detail |
The phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway plays a cr... | DisGeNET | Detail |
Together, these results demonstrate that HGF/c-met can activate PI3K/Akt and downstream NF-κB signal... | DisGeNET | Detail |
Mechanistic studies further revealed that VAV3 overexpression could dysregulate the expression of ce... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
We suggest that Nutlin-3, possibly in combination with FAK or PI3K inhibitors, can be employed as a ... | DisGeNET | Detail |
Moreover, inhibitors of PI3K/mTOR and GLI signaling reduced neuroblastoma cell growth, but no additi... | DisGeNET | Detail |
Molecular rationale for the use of PI3K/AKT/mTOR pathway inhibitors in combination with crizotinib i... | DisGeNET | Detail |
We previously demonstrated that PI3K Class IIβ (PI3KC2β) and its regulator intersectin 1 (ITSN1) are... | DisGeNET | Detail |
NA | DisGeNET | Detail |
This integrated view of PI3K functions may ultimately help to develop new therapeutic interventions ... | DisGeNET | Detail |
NA | DisGeNET | Detail |
Knockdown of CXCR7 suppressed proliferation and invasion of OS cells through decreased expression of... | DisGeNET | Detail |
The present results indicated that LY294002 inhibits the malignant phenotype of OS cells via modulat... | DisGeNET | Detail |
Complementary genomic approaches highlight the PI3K/mTOR pathway as a common vulnerability in osteos... | DisGeNET | Detail |
In conclusion, icariin possesses a reversal effect on multidrug resistance in MG-63/DOX cells throug... | DisGeNET | Detail |
Re-expression of ARHI in ovarian cancer cells blocks signaling through the PI3K and Ras/MAP pathways... | DisGeNET | Detail |
MicroRNA-497 suppresses angiogenesis by targeting vascular endothelial growth factor A through the P... | DisGeNET | Detail |
Inhibiting the PI3K/AKT pathway may be a useful treatment for ovarian carcinoma. | DisGeNET | Detail |
Moreover, LY294002, a potent and specific cell-permeable inhibitor of phosphatidylinositol 3-kinases... | DisGeNET | Detail |
The PI3K/AKT/mTOR pathway as a therapeutic target in ovarian cancer. | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
In type 2 diabetes, obesity and PCOS, there is, although with some variation from study to study, de... | DisGeNET | Detail |
NA | DisGeNET | Detail |
PTEN inactivation by mutation or allelic loss also occurs in CRCs. miR‑135b was reported to be upreg... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Genome-wide analyses have identified four major signaling nodes that are most frequently altered in ... | DisGeNET | Detail |
PIK3R3, an isoform of class IA phosphoinositide 3-kinase (PI3K), specifically interacts with cell pr... | DisGeNET | Detail |
In the present study, we searched for combination therapies with the dual PI3K/mTOR inhibitor NVP-BE... | DisGeNET | Detail |
Thus, combined GLI1/2 and PI3K/mTOR inhibition represents a promising novel approach for synergistic... | DisGeNET | Detail |
The aim of our study was to investigate whether common polymorphisms in the genes regulating the ear... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
These data are the first to demonstrate that the inflammatory response induced by IL-1β promotes sei... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
We have already shown that AKT is activated in skin lesions in Mycosis Fungoides (MF) and we herein ... | DisGeNET | Detail |
NA | DisGeNET | Detail |
In conclusion, IL-8 stimulates VEGF production in hBM-MSCs in part via the PI3K/Akt and MAPK/ERK sig... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
In addition, the phosphoinositide-3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) pathway w... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
The phosphatidylinositol-3-kinase (PI3K) and Akt pathway is activated in host immune cells upon vira... | DisGeNET | Detail |
Many alterations directly or indirectly lead to activation of survival signaling pathways and expres... | DisGeNET | Detail |
The oncogenic PI3K/serine-threonine kinase (PI3K/AKT) pathway is a downstream pathway of B-cell rece... | DisGeNET | Detail |
Inhibition of the PI3K/Akt/mTOR signaling pathway in diffuse large B-cell lymphoma: current knowledg... | DisGeNET | Detail |
NA | DisGeNET | Detail |
We suggest that targeting the PI3K/AKT pathway may be a promising therapeutic strategy for PTCL. | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
This study reveals a critical role for the PTEN/PI3K pathway in both SCLC and lung adenocarcinoma an... | DisGeNET | Detail |
The PI3K/AKT/mTOR pathway is distinguishable in SCLC genomic alterations. | DisGeNET | Detail |
NA | DisGeNET | Detail |
bFGF regulates autophagy and ubiquitinated protein accumulation induced by myocardial ischemia/reper... | DisGeNET | Detail |
These data identify RIT1 as a driver oncogene in a specific subset of lung adenocarcinomas and sugge... | DisGeNET | Detail |
This study reveals a critical role for the PTEN/PI3K pathway in both SCLC and lung adenocarcinoma an... | DisGeNET | Detail |
ERBB3-independent activation of the PI3K pathway in EGFR-mutant lung adenocarcinomas. | DisGeNET | Detail |
Signaling through the Phosphatidylinositol 3-Kinase (PI3K)/Mammalian Target of Rapamycin (mTOR) Axis... | DisGeNET | Detail |
Therefore, concomitant blockage of the ErbB2-PI3K pathway and the Hedgehog downstream mediator Gli-1... | DisGeNET | Detail |
Immunohistochemical and molecular analysis of PI3K/AKT/mTOR pathway in esophageal carcinoma. | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
We found that activation of the PI3K/Akt pathway was involved in the oncogenic functions of SPOCK1 i... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
We propose the simultaneous activation of PLC-PKC-MEK1/2-ERK1/2 and PI3K pathways as the main mechan... | DisGeNET | Detail |
These findings uncover a mechanism for constitutive PI3K/Akt activation in ESCC, and support a funct... | DisGeNET | Detail |
Our data showed that the PTEN/PI3K pathway was active in human ESCC tissues in vivo, particularly in... | DisGeNET | Detail |
The PI3K/AKT signal transduction pathway has distinct functional roles in tumor progression. | DisGeNET | Detail |
NA | DisGeNET | Detail |
In addition to the commonly known AP-1 activators Mitogen-Activated Protein Kinases (MAPKs), there a... | DisGeNET | Detail |
Anticancer effect of calycopterin via PI3K/Akt and MAPK signaling pathways, ROS-mediated pathway and... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Crosstalk between PI3K and Ras pathways via protein phosphatase 2A in human ovarian clear cell carci... | DisGeNET | Detail |
NA | DisGeNET | Detail |
Preclinical investigations have suggested that the PI3K/AKT/mTOR pathway is frequently activated in ... | DisGeNET | Detail |
The efficacy of both PI3K and MEK inhibitors was evaluated in a model of endometrioid carcinoma harb... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Neuroendocrine cancer cell lines are used to investigate therapeutic targets in neuroendocrine tumor... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
We found that activation of the PI3K/Akt pathway was involved in the oncogenic functions of SPOCK1 i... | DisGeNET | Detail |
Further analysis showed that Cyr61 seemed to activate phosphatidylinositol 3-kinase (PI3K) but not e... | DisGeNET | Detail |
Recent data identify 3-phosphoinositide-dependent protein kinase 1 as a key tumour-initiating event ... | DisGeNET | Detail |
Activation of phosphoinositide-3 kinase (PI3K)-AKT-mammalian target of rapamycin (mTOR) pathway play... | DisGeNET | Detail |
Taken together, these data indicate that inhibition of MEK and PI3K alone or in combination with che... | DisGeNET | Detail |
microRNA-218 increase the sensitivity of gastrointestinal stromal tumor to imatinib through PI3K/AKT... | DisGeNET | Detail |
We tested the in vivo efficacy of three PI3K inhibitors (PI3Ki) in patient-derived GIST xenograft mo... | DisGeNET | Detail |
NA | DisGeNET | Detail |
Here, we outlined the common pathways that are altered in ATC, including the BRAF(V600E)/ERK1/2-MEK1... | DisGeNET | Detail |
PI3K/Akt/mTOR: A promising therapeutic target for non-medullary thyroid carcinoma. | DisGeNET | Detail |
NA | DisGeNET | Detail |
RNA interference-mediated knockdown of RhoGDI2 induces the migration and invasion of human lung canc... | DisGeNET | Detail |
Common molecular drivers of lung cancer are mutations in receptor tyrosine kinases (RTKs) leading to... | DisGeNET | Detail |
When the chimeric ubiquitin ligases were introduced into lung cancer SPC-A1 cells, they effectively ... | DisGeNET | Detail |
The altered PI3K/mTOR pathway is implicated in lung cancer, but mTOR inhibitors have failed to demon... | DisGeNET | Detail |
It was found that AKT1 and PI3K/p85 expression was upregulated in LCSCs compared with that in the pr... | DisGeNET | Detail |
Hepatocyte growth factor (HGF) induces resistance to reversible and irreversible epidermal growth fa... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Genome-wide analyses have identified four major signaling nodes that are most frequently altered in ... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Here, resistance to a class I PI3K inhibitor in a model of metastatic breast cancer driven by PI3K a... | DisGeNET | Detail |
Molecular aberrations affecting the PI3K pathway may play a role in the progression from high-grade ... | DisGeNET | Detail |
NA | DisGeNET | Detail |
Activation of the PI3K/AKT signal pathway is a known driving force for the progression to castration... | DisGeNET | Detail |
Macrophage migration inhibitory factor engages PI3K/Akt signalling and is a prognostic factor in met... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Our studies indicate that CK2-mediated PTEN posttranslational inactivation, associated with PI3K/Akt... | DisGeNET | Detail |
Disruption of the PTEN/PI3K pathway involved in TGF-β1-induced EMT may provide possible routes for t... | DisGeNET | Detail |
Notably, high activity of hedgehog signaling and the PI3K pathway in approximately 60% of 104 ESCC t... | DisGeNET | Detail |
Dasatinib enhances cisplatin sensitivity in human esophageal squamous cell carcinoma (ESCC) cells vi... | DisGeNET | Detail |
ErbB2 signaling activates the Hedgehog pathway via PI3K-Akt in human esophageal adenocarcinoma: iden... | DisGeNET | Detail |
The objective of this study was to investigate the predictive value of common genetic alterations of... | DisGeNET | Detail |
Loss of MLH1 confers resistance to PI3Kβ inhibitors in renal clear cell carcinoma with SETD2 mutatio... | DisGeNET | Detail |
We identified the selective PI3Kβ inhibitor TGX221 as a selective inhibitor for ccRCC with both VHL ... | DisGeNET | Detail |
High selectivity of PI3Kβ inhibitors in SETD2-mutated renal clear cell carcinoma. | DisGeNET | Detail |
First-in-human phase I study of pictilisib (GDC-0941), a potent pan-class I phosphatidylinositol-3-k... | DisGeNET | Detail |
BYL719, which selectively inhibits the alpha isoform of the phosphatidylinositol 3-kinase (PI3K) cat... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Taken together, our data suggest that anti-VEGFa treatment in cervical cancer may inhibit both tumor... | DisGeNET | Detail |
CD38 is highly expressed and affects the PI3K/Akt signaling pathway in cervical cancer. | DisGeNET | Detail |
Peroxisome proliferator-activated receptor-gamma agonist 4-O-methylhonokiol induces apoptosis by tri... | DisGeNET | Detail |
The phosphatase and tensin homolog deleted on chromosome 10 (PTEN) protein is principally involved i... | DisGeNET | Detail |
Butein suppresses cervical cancer growth through the PI3K/AKT/mTOR pathway. | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
In this study, the inhibitory effect of KYNA on activation of phosphoinositide 3-kinase/Akt (PI3K/Ak... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Recent data identify 3-phosphoinositide-dependent protein kinase 1 as a key tumour-initiating event ... | DisGeNET | Detail |
Activation of phosphoinositide-3 kinase (PI3K)-AKT-mammalian target of rapamycin (mTOR) pathway play... | DisGeNET | Detail |
Taken together, these data indicate that inhibition of MEK and PI3K alone or in combination with che... | DisGeNET | Detail |
First-in-human study of CH5132799, an oral class I PI3K inhibitor, studying toxicity, pharmacokineti... | DisGeNET | Detail |
Juvenile myelomonocytic leukaemia-associated mutation in Cbl promotes resistance to apoptosis via th... | DisGeNET | Detail |
We identified differential therapeutic vulnerabilities that emerge upon the loss of both PTEN and p5... | DisGeNET | Detail |
A genome-wide RNAi screen identifies FOXO4 as a metastasis-suppressor through counteracting PI3K/AKT... | DisGeNET | Detail |
The impact of miRNA on the canonical TGF-β Smad signalling pathway has been well investigated, hence... | DisGeNET | Detail |
Restoration of PTEN expression or inhibition of PI3K action decreased cPLA₂α expression in PTEN-muta... | DisGeNET | Detail |
Genome-wide analyses have identified four major signaling nodes that are most frequently altered in ... | DisGeNET | Detail |
Targeting the PI3K/Akt pathway in prostate cancer: challenges and opportunities (review). | DisGeNET | Detail |
The findings from this study suggest that the combination of dual PI3K/Akt/mTOR inhibitors (BEZ235 o... | DisGeNET | Detail |
Co-targeting AR and PI3K/AKT signaling has been proposed to be a more effective therapeutic means fo... | DisGeNET | Detail |
The Upregulation of PI3K/Akt and MAP Kinase Pathways is Associated with Resistance of Microtubule-Ta... | DisGeNET | Detail |
Among the cancer networks and STNs we considered, it is found that there is a substantial amount of ... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
The activation of a central growth/survival pathway (PI3K/AKT) represents a feasible target for the ... | DisGeNET | Detail |
NA | DisGeNET | Detail |
Endometrial cancers have been recently molecularly characterized; amplifications of human epidermal ... | DisGeNET | Detail |
The impact of microRNA-mediated PI3K/AKT signaling on epithelial-mesenchymal transition and cancer s... | DisGeNET | Detail |
This article reviews the results of Phase II clinical trials of PI3K/Akt/mTOR pathway inhibitors in ... | DisGeNET | Detail |
The phosphoinositol-3 kinase (PI3K) pathway is frequently dysregulated in endometrial cancer (EC). | DisGeNET | Detail |
PIKing the type and pattern of PI3K pathway mutations in endometrioid endometrial carcinomas. | DisGeNET | Detail |
NEDD4 ubiquitin ligase is a putative oncogene in endometrial cancer that activates IGF-1R/PI3K/Akt s... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Other molecular alterations, like mTOR or PI3K pathway deregulation, or Matrilin 2 overexpression, m... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Therefore, concomitant blockage of the ErbB2-PI3K pathway and the Hedgehog downstream mediator Gli-1... | DisGeNET | Detail |
The present review focuses on the most recent developments on the role of the PI3K/Akt pathway in th... | DisGeNET | Detail |
We further show that expression of PTEN, a well-established, potent tumor suppressor, is lost in a s... | DisGeNET | Detail |
Y-box Binding Protein-1 Is Part of a Complex Molecular Network Linking ΔNp63α to the PI3K/akt Pathwa... | DisGeNET | Detail |
NA | DisGeNET | Detail |
Divergence of P53, PTEN, PI3K, Akt and mTOR expression in tonsillar cancer. | DisGeNET | Detail |
NA | DisGeNET | Detail |
Knockdown of CXCR7 suppressed proliferation and invasion of OS cells through decreased expression of... | DisGeNET | Detail |
The present results indicated that LY294002 inhibits the malignant phenotype of OS cells via modulat... | DisGeNET | Detail |
Complementary genomic approaches highlight the PI3K/mTOR pathway as a common vulnerability in osteos... | DisGeNET | Detail |
In conclusion, icariin possesses a reversal effect on multidrug resistance in MG-63/DOX cells throug... | DisGeNET | Detail |
Costello syndrome (CS) is a rare genetic disorder caused, in the majority of cases, by germline miss... | DisGeNET | Detail |
NA | DisGeNET | Detail |
When combined with previous studies, our data suggest that dual induction of PAR-2-NFκB inflammatory... | DisGeNET | Detail |
The phosphatidylinositol 3-kinase (PI3K), MAP kinase (MAPK), and related pathways are implicated in ... | DisGeNET | Detail |
R-Ras2 drives tumorigenesis in a phosphatidylinostiol-3 kinase (PI3K)-dependent and signalling auton... | DisGeNET | Detail |
We further show that superactivation of the prosurvival PI3K-AKT signaling pathway limits the effica... | DisGeNET | Detail |
These findings further suggest that regulation of SUMOylation by PI3K/Akt signaling is likely an imp... | DisGeNET | Detail |
The findings indicate that epigenetic inactivation of INPP4B is one of the key mechanisms in activat... | DisGeNET | Detail |
Furthermore, miR-200a induces cell transformation and tumorigenesis in immunocompromised mice by coo... | DisGeNET | Detail |
We here demonstrate that PIK3CA mutations, PTEN loss, PI3K and KRAS activation are early events in e... | DisGeNET | Detail |
Phosphatidylinositol 3-kinases (PI3Ks) play important roles in human tumorigenesis. | DisGeNET | Detail |
Given the contribution of HRG signaling and the PI3K-Akt pathway in particular to tumorigenesis, thi... | DisGeNET | Detail |
The PI3K/Akt and MAP kinase pathways play important roles in a variety of normal cellular processes ... | DisGeNET | Detail |
Single nucleotide polymorphisms (SNPs) in the PI3K/PTEN/AKT/mTOR signaling pathway may contribute to... | DisGeNET | Detail |
Pathways known to affect tumorigenesis across a wide spectrum of tissues are dysregulated, such as t... | DisGeNET | Detail |
The phosphoinositide 3-kinase (PI3K)/Akt signaling pathway appears to be a key regulator in cervical... | DisGeNET | Detail |
Our findings support the de-regulation of the PI3K/Akt/mTOR and MAPK signaling pathways in type I en... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
We identified differential therapeutic vulnerabilities that emerge upon the loss of both PTEN and p5... | DisGeNET | Detail |
A genome-wide RNAi screen identifies FOXO4 as a metastasis-suppressor through counteracting PI3K/AKT... | DisGeNET | Detail |
The impact of miRNA on the canonical TGF-β Smad signalling pathway has been well investigated, hence... | DisGeNET | Detail |
Restoration of PTEN expression or inhibition of PI3K action decreased cPLA₂α expression in PTEN-muta... | DisGeNET | Detail |
Genome-wide analyses have identified four major signaling nodes that are most frequently altered in ... | DisGeNET | Detail |
Targeting the PI3K/Akt pathway in prostate cancer: challenges and opportunities (review). | DisGeNET | Detail |
The findings from this study suggest that the combination of dual PI3K/Akt/mTOR inhibitors (BEZ235 o... | DisGeNET | Detail |
Co-targeting AR and PI3K/AKT signaling has been proposed to be a more effective therapeutic means fo... | DisGeNET | Detail |
The Upregulation of PI3K/Akt and MAP Kinase Pathways is Associated with Resistance of Microtubule-Ta... | DisGeNET | Detail |
Among the cancer networks and STNs we considered, it is found that there is a substantial amount of ... | DisGeNET | Detail |
Inhibiting the PI3K/AKT pathway may be a useful treatment for ovarian carcinoma. | DisGeNET | Detail |
In conclusion, the results of the present study demonstrated that PI3K/AKT and Rab25 significantly c... | DisGeNET | Detail |
These findings revealed that miR‑338‑3p may act as a tumor suppressor that blocks the growth of huma... | DisGeNET | Detail |
Therefore, the hyperactivity of PI3K/Akt pathway and elevated levels of p53R2 can give rise to highl... | DisGeNET | Detail |
NA | DisGeNET | Detail |
Direct inhibition of PI3K in combination with dual HER2 inhibitors is required for optimal antitumor... | DisGeNET | Detail |
Characterization of breast cancers with PI3K mutations in an academic practice setting using SNaPsho... | DisGeNET | Detail |
Their prognostic value and that of the phosphatidylinositol 3-kinase (PI3K) pathway in BC remains on... | DisGeNET | Detail |
Phosphatidylinositol 3-kinase (PI3K) pathway deregulation (that is PIK3CA mutations and/or phosphata... | DisGeNET | Detail |
Western blot analysis data indicate that MAPK/ERK and PI3K/Akt signaling in breast cancer cells with... | DisGeNET | Detail |
Microarray phosphatome profiling of breast cancer patients unveils a complex phosphatase regulatory ... | DisGeNET | Detail |
In the present study, we have shown for the first time that HBA decreased the expression of phosphot... | DisGeNET | Detail |
Axl as a downstream effector of TGF-β1 via PI3K/Akt-PAK1 signaling pathway promotes tumor invasion a... | DisGeNET | Detail |
Regulation of the cell cycle and PI3K/Akt/mTOR signaling pathway by tanshinone I in human breast can... | DisGeNET | Detail |
LYN(D189Y) overexpression abrogated growth inhibition by fulvestrant and/or the PI3K inhibitor BKM12... | DisGeNET | Detail |
Phosphatidylinositol-3-kinase (PI3K)/AKT pathway mutations are associated with cancer and phosphatid... | DisGeNET | Detail |
The PI3K/mTOR dual inhibitor P7170 demonstrates potent activity against endocrine-sensitive and endo... | DisGeNET | Detail |
In conclusion, activating the PI3K pathway is associated with low pCR to trastuzumab-based treatment... | DisGeNET | Detail |
Estrogen-responsive genes most significantly influenced by cohesin were enriched in pathways associa... | DisGeNET | Detail |
BYL719, which selectively inhibits the alpha isoform of the phosphatidylinositol 3-kinase (PI3K) cat... | DisGeNET | Detail |
We investigated whether mutations in the gene encoding the phosphatidylinositol 3-kinase (PI3K) cata... | DisGeNET | Detail |
In the present study, we demonstrate that PI3K pathway regulates phenotypic changes in breast cancer... | DisGeNET | Detail |
Further, PI3K is thought to be the main driver of lapatinib resistance, but our findings indicate th... | DisGeNET | Detail |
The epidermal growth factor receptor (EGFR)/PI3K/AKT signaling pathway aberrations play significant ... | DisGeNET | Detail |
In the present study, the protein expression levels of SET, protein phosphatase 2A (PP2A) and phosph... | DisGeNET | Detail |
PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor-po... | DisGeNET | Detail |
IL-8/PI3K/Akt/NF-κB/integrin β3 axis may be exploited for therapeutic intervention to breast cancer ... | DisGeNET | Detail |
Beyond ER and HER2, BRCA and PIK3CA mutations (when targeted with alpha-specific PI3K inhibitors) co... | DisGeNET | Detail |
Taken together, the prostacyclin/IP/PI3K-p38 MAPK axis has emerged as a novel pro-migratory pathway ... | DisGeNET | Detail |
Resistance to trastuzumab in patients with HER2-overexpressing breast cancer is associated with high... | DisGeNET | Detail |
Collectively, our findings identify PIPP as a suppressor of oncogenic PI3K/AKT signaling in breast c... | DisGeNET | Detail |
Inhibition of Autophagy Increases Proliferation Inhibition and Apoptosis Induced by the PI3K/mTOR In... | DisGeNET | Detail |
RNA interference-mediated knockdown of RhoGDI2 induces the migration and invasion of human lung canc... | DisGeNET | Detail |
Common molecular drivers of lung cancer are mutations in receptor tyrosine kinases (RTKs) leading to... | DisGeNET | Detail |
When the chimeric ubiquitin ligases were introduced into lung cancer SPC-A1 cells, they effectively ... | DisGeNET | Detail |
The altered PI3K/mTOR pathway is implicated in lung cancer, but mTOR inhibitors have failed to demon... | DisGeNET | Detail |
It was found that AKT1 and PI3K/p85 expression was upregulated in LCSCs compared with that in the pr... | DisGeNET | Detail |
Hepatocyte growth factor (HGF) induces resistance to reversible and irreversible epidermal growth fa... | DisGeNET | Detail |
Our data showed that the PTEN/PI3K pathway was active in human ESCC tissues in vivo, particularly in... | DisGeNET | Detail |
Synergism of PI3K/Akt inhibition and Fas activation on colon cancer cell death. | DisGeNET | Detail |
Quinazoline based small molecule exerts potent tumour suppressive properties by inhibiting PI3K/Akt/... | DisGeNET | Detail |
In the present study, the expression status of miR-218 and the role of the phosphoinositide 3-kinase... | DisGeNET | Detail |
Combined ginger extract & Gelam honey modulate Ras/ERK and PI3K/AKT pathway genes in colon cancer HT... | DisGeNET | Detail |
Here, we detected its effects on DLD-1 and SW480 (two human colon cancer cell lines) and investigate... | DisGeNET | Detail |
These data suggest that EGF-induced activation of MMP7 and MMP13 in GC is through phosphatidylinosit... | DisGeNET | Detail |
In conclusion, knockdown of the c‑Met gene promoted gastric cancer cell apoptosis and inhibited down... | DisGeNET | Detail |
Mechanically, PTP1B promotes gastric cancer cell proliferation, survival and invasiveness through mo... | DisGeNET | Detail |
Therefore, our studies reveal for the first time that inhibition of the PI3K-Akt pathway is involved... | DisGeNET | Detail |
Hepatocyte growth factor (HGF) upregulates heparanase expression via the PI3K/Akt/NF-κB signaling pa... | DisGeNET | Detail |
These findings may have high relevance in terms of using PI3K-targeted therapies for BC treatment. | DisGeNET | Detail |
Targeting the genetic alterations of the PI3K-AKT-mTOR pathway: its potential use in the treatment o... | DisGeNET | Detail |
Our findings suggest that miR-21 acts as a molecular switch to regulate aerobic glycolysis in bladde... | DisGeNET | Detail |
Taken together, EN2 may be a candidate oncogene in BC by activating the PI3K/Akt pathway and inhibit... | DisGeNET | Detail |
This article reviews the results of Phase II clinical trials of PI3K/Akt/mTOR pathway inhibitors in ... | DisGeNET | Detail |
NA | DisGeNET | Detail |
Moreover, inhibitors of PI3K/mTOR and GLI signaling reduced neuroblastoma cell growth, but no additi... | DisGeNET | Detail |
Molecular rationale for the use of PI3K/AKT/mTOR pathway inhibitors in combination with crizotinib i... | DisGeNET | Detail |
We previously demonstrated that PI3K Class IIβ (PI3KC2β) and its regulator intersectin 1 (ITSN1) are... | DisGeNET | Detail |
NA | DisGeNET | Detail |
Targeted inhibition of the PI3K/mTOR and Hhpathways indicates a new avenue for BTC treatment with co... | DisGeNET | Detail |
Divergence of P53, PTEN, PI3K, Akt and mTOR expression in tonsillar cancer. | DisGeNET | Detail |
NA | DisGeNET | Detail |
MET and PI3K/mTOR as a potential combinatorial therapeutic target in malignant pleural mesothelioma. | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Inhibition of PI3K and Akt kinase prevented the phosphorylation of 4E-BP1, suggesting that PI3K sign... | DisGeNET | Detail |
PI3K pathway activation in high-grade ductal carcinoma in situ--implications for progression to inva... | DisGeNET | Detail |
Our model allowed us to test the contributions of oncogenes in the RTK/RAS/PI(3)K pathway, and their... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
In this study we performed multiplex targeted sequencing of 10 genes in the PI3K/AKT pathway on brai... | DisGeNET | Detail |
Re-expression of ARHI in ovarian cancer cells blocks signaling through the PI3K and Ras/MAP pathways... | DisGeNET | Detail |
MicroRNA-497 suppresses angiogenesis by targeting vascular endothelial growth factor A through the P... | DisGeNET | Detail |
Moreover, LY294002, a potent and specific cell-permeable inhibitor of phosphatidylinositol 3-kinases... | DisGeNET | Detail |
The PI3K/AKT/mTOR pathway as a therapeutic target in ovarian cancer. | DisGeNET | Detail |
NA | DisGeNET | Detail |
A comprehensive evaluation of biomarkers predictive of response to PI3K inhibitors and of resistance... | DisGeNET | Detail |
Additional study is required to develop new model systems and approaches to determine the role of ta... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Herein, we will review the clinically relevant inhibitors of the PI3K pathway that have been evaluat... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Our results show that Sendai virus infection, which is recognized by RIG-I, led to IRF3 activation a... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Curcumin significantly enhances dual PI3K/Akt and mTOR inhibitor NVP-BEZ235-induced apoptosis in hum... | DisGeNET | Detail |
Targeted PI3K/AKT/mTOR therapy for metastatic carcinomas of the cervix: A phase I clinical experienc... | DisGeNET | Detail |
We validated the top ranking genes, i.e., PIK3CA and PIK3CB, by showing that their forced expression... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
The tumor suppressor WIF1 was also found to be capable of suppressing tumor growth through the inhib... | DisGeNET | Detail |
Increased CYP4Z2P- and CYP4Z1-3'UTR expression promotes tumor angiogenesis in breast cancer partly v... | DisGeNET | Detail |
NA | DisGeNET | Detail |
The combination of HER2 inhibitors with PI3K inhibition was studied in HER2-amplified xenograft mode... | DisGeNET | Detail |
Using AR + TNBC cell line and xenograft models we evaluated the effectiveness of PI3K inhibitors, us... | DisGeNET | Detail |
In addition, the phosphoinositide-3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) pathway w... | DisGeNET | Detail |
We tested the in vivo efficacy of three PI3K inhibitors (PI3Ki) in patient-derived GIST xenograft mo... | DisGeNET | Detail |
The added predictive value of additional biomarkers in the RAS-RAF-MAPK and PI3K-AKT-mTOR pathways i... | DisGeNET | Detail |
The role of c2orf68 and PI3K/Akt/mTOR pathway in human colorectal cancer. | DisGeNET | Detail |
These data indicate that the capacity of retinol to inhibit PI3K activity confers its ability to dec... | DisGeNET | Detail |
We conclude that cPLA2α is required for sustaining AKT phosphorylation at Ser473 and cell proliferat... | DisGeNET | Detail |
Inhibitors against KRAS signaling mediators, namely, PI3K (phosphatidylinositol 3-kinase) and mTOR (... | DisGeNET | Detail |
PTEN inactivation by mutation or allelic loss also occurs in CRCs. miR‑135b was reported to be upreg... | DisGeNET | Detail |
The role of the PI3K pathway in colorectal cancer. | DisGeNET | Detail |
Mutations in the RAS and PI3K pathways are associated with metastatic location in colorectal cancers... | DisGeNET | Detail |
Eight of these genes were linked to the Wnt, Hippo, TGF-β, EGF receptor, or PI3K pathways, all invol... | DisGeNET | Detail |
NA | DisGeNET | Detail |
Preclinical investigations have suggested that the PI3K/AKT/mTOR pathway is frequently activated in ... | DisGeNET | Detail |
Here, using specific inhibitors, we found that the activation of EGFR signaling promoted GBM growth ... | DisGeNET | Detail |
The phosphoinositide 3-kinase (PI3K)/Akt/PTEN signaling pathway is deregulated in GBM. | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Important mechanisms we discuss include (1) improved DNA repair in normal, but not tumor cells; (2) ... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Although the mutation rates and mutational signatures of MSS and MSI-H EECs were distinct, the preva... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
The impact of microRNA-mediated PI3K/AKT signaling on epithelial-mesenchymal transition and cancer s... | DisGeNET | Detail |
This article reviews the results of Phase II clinical trials of PI3K/Akt/mTOR pathway inhibitors in ... | DisGeNET | Detail |
The phosphoinositol-3 kinase (PI3K) pathway is frequently dysregulated in endometrial cancer (EC). | DisGeNET | Detail |
NEDD4 ubiquitin ligase is a putative oncogene in endometrial cancer that activates IGF-1R/PI3K/Akt s... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
In this review, we summarize the existing knowledge of the relevance of Notch1 and PI3K/Akt/mTOR sig... | DisGeNET | Detail |
We also explored the molecular mechanism of FHL1C overexpression-induced apoptosis, which suppressed... | DisGeNET | Detail |
High activation of the PI3K-AKT-mTOR pathway is characteristic for T-cell acute lymphoblastic leukem... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
This mode of action for calycopterin in our study provides strong support that inhibition of PI3K/Ak... | DisGeNET | Detail |
The PI3K/Akt/Snail-dependent pathway may mediate the pro-invasive and pro-metastatic effects of sora... | DisGeNET | Detail |
The inhibition of PI3K/Akt activation abolished epithelial-mesenchymal transition (EMT) and invasion... | DisGeNET | Detail |
Bioinformatic method was applied to predict the binding of miR-218 on HoxA10, and western blotting w... | DisGeNET | Detail |
In clinical HCC samples, high expression of both CXCR2 and CXCL5 showed a significant correlation wi... | DisGeNET | Detail |
The purpose of this study was to determine the impact of sorafenib on PI3K/AKT/mTOR signaling pathwa... | DisGeNET | Detail |
HBx induced AFP receptor expressed to activate PI3K/AKT signal to promote expression of Src in liver... | DisGeNET | Detail |
Down-Regulated NRSN2 Promotes Cell Proliferation and Survival Through PI3K/Akt/mTOR Pathway in Hepat... | DisGeNET | Detail |
Moreover, LIFR knockdown could activate phosphoinositide 3-kinase/V-akt Murine Thymoma Viral Oncogen... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Role of selenoprotein S (SEPS1) -105G>A polymorphisms and PI3K/Akt signaling pathway in Kashin-Beck ... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Epigenetic inactivation of inositol polyphosphate 4-phosphatase B (INPP4B), a regulator of PI3K/AKT ... | DisGeNET | Detail |
The current study demonstrated that EphA2 mediates sensitivity to paclitaxel via the regulation of t... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Mutations in PIK3CA, the gene encoding the p110α catalytic subunit of PI3K, are among the most commo... | DisGeNET | Detail |
NA | DisGeNET | Detail |
The PI3K/AKT/mTOR (PAM) signaling pathway controls key cellular responses, such as cell growth and p... | DisGeNET | Detail |
NA | DisGeNET | Detail |
Different targeted therapies may be necessary for TNBC that involves activation of PI3K/AKT or MAPK ... | DisGeNET | Detail |
PIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to t... | DisGeNET | Detail |
Mutational profiles in triple-negative breast cancer defined by ultradeep multigene sequencing show ... | DisGeNET | Detail |
β-TrCP1 degradation is a novel action mechanism of PI3K/mTOR inhibitors in triple-negative breast ca... | DisGeNET | Detail |
Activation of the phosphatidylinositol-3-kinase (PI3K) and/or mitogen-activated protein kinase (MAPK... | DisGeNET | Detail |
Activation of the phosphatidylinositol 3-kinase (PI3K)/AKT/mTOR pathway has been implicated in anti-... | DisGeNET | Detail |
NA | DisGeNET | Detail |
Brain overgrowth in disorders of RTK-PI3K-AKT signaling: a mosaic of malformations. | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Following stimulation with 10 nM insulin for 30 min, the stable overexpression of Arg972 IRS-1 and k... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
These findings may have high relevance in terms of using PI3K-targeted therapies for BC treatment. | DisGeNET | Detail |
Targeting the genetic alterations of the PI3K-AKT-mTOR pathway: its potential use in the treatment o... | DisGeNET | Detail |
Our findings suggest that miR-21 acts as a molecular switch to regulate aerobic glycolysis in bladde... | DisGeNET | Detail |
Taken together, EN2 may be a candidate oncogene in BC by activating the PI3K/Akt pathway and inhibit... | DisGeNET | Detail |
NA | DisGeNET | Detail |
Direct inhibition of PI3K in combination with dual HER2 inhibitors is required for optimal antitumor... | DisGeNET | Detail |
Characterization of breast cancers with PI3K mutations in an academic practice setting using SNaPsho... | DisGeNET | Detail |
Their prognostic value and that of the phosphatidylinositol 3-kinase (PI3K) pathway in BC remains on... | DisGeNET | Detail |
Phosphatidylinositol 3-kinase (PI3K) pathway deregulation (that is PIK3CA mutations and/or phosphata... | DisGeNET | Detail |
Western blot analysis data indicate that MAPK/ERK and PI3K/Akt signaling in breast cancer cells with... | DisGeNET | Detail |
Microarray phosphatome profiling of breast cancer patients unveils a complex phosphatase regulatory ... | DisGeNET | Detail |
In the present study, we have shown for the first time that HBA decreased the expression of phosphot... | DisGeNET | Detail |
Axl as a downstream effector of TGF-β1 via PI3K/Akt-PAK1 signaling pathway promotes tumor invasion a... | DisGeNET | Detail |
Regulation of the cell cycle and PI3K/Akt/mTOR signaling pathway by tanshinone I in human breast can... | DisGeNET | Detail |
LYN(D189Y) overexpression abrogated growth inhibition by fulvestrant and/or the PI3K inhibitor BKM12... | DisGeNET | Detail |
Phosphatidylinositol-3-kinase (PI3K)/AKT pathway mutations are associated with cancer and phosphatid... | DisGeNET | Detail |
The PI3K/mTOR dual inhibitor P7170 demonstrates potent activity against endocrine-sensitive and endo... | DisGeNET | Detail |
In conclusion, activating the PI3K pathway is associated with low pCR to trastuzumab-based treatment... | DisGeNET | Detail |
Estrogen-responsive genes most significantly influenced by cohesin were enriched in pathways associa... | DisGeNET | Detail |
BYL719, which selectively inhibits the alpha isoform of the phosphatidylinositol 3-kinase (PI3K) cat... | DisGeNET | Detail |
We investigated whether mutations in the gene encoding the phosphatidylinositol 3-kinase (PI3K) cata... | DisGeNET | Detail |
In the present study, we demonstrate that PI3K pathway regulates phenotypic changes in breast cancer... | DisGeNET | Detail |
Further, PI3K is thought to be the main driver of lapatinib resistance, but our findings indicate th... | DisGeNET | Detail |
The epidermal growth factor receptor (EGFR)/PI3K/AKT signaling pathway aberrations play significant ... | DisGeNET | Detail |
In the present study, the protein expression levels of SET, protein phosphatase 2A (PP2A) and phosph... | DisGeNET | Detail |
PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor-po... | DisGeNET | Detail |
IL-8/PI3K/Akt/NF-κB/integrin β3 axis may be exploited for therapeutic intervention to breast cancer ... | DisGeNET | Detail |
Beyond ER and HER2, BRCA and PIK3CA mutations (when targeted with alpha-specific PI3K inhibitors) co... | DisGeNET | Detail |
Taken together, the prostacyclin/IP/PI3K-p38 MAPK axis has emerged as a novel pro-migratory pathway ... | DisGeNET | Detail |
Resistance to trastuzumab in patients with HER2-overexpressing breast cancer is associated with high... | DisGeNET | Detail |
Collectively, our findings identify PIPP as a suppressor of oncogenic PI3K/AKT signaling in breast c... | DisGeNET | Detail |
Inhibition of Autophagy Increases Proliferation Inhibition and Apoptosis Induced by the PI3K/mTOR In... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Synergism of PI3K/Akt inhibition and Fas activation on colon cancer cell death. | DisGeNET | Detail |
Quinazoline based small molecule exerts potent tumour suppressive properties by inhibiting PI3K/Akt/... | DisGeNET | Detail |
In the present study, the expression status of miR-218 and the role of the phosphoinositide 3-kinase... | DisGeNET | Detail |
Combined ginger extract & Gelam honey modulate Ras/ERK and PI3K/AKT pathway genes in colon cancer HT... | DisGeNET | Detail |
Here, we detected its effects on DLD-1 and SW480 (two human colon cancer cell lines) and investigate... | DisGeNET | Detail |
The impact of microRNA-mediated PI3K/AKT signaling on epithelial-mesenchymal transition and cancer s... | DisGeNET | Detail |
This article reviews the results of Phase II clinical trials of PI3K/Akt/mTOR pathway inhibitors in ... | DisGeNET | Detail |
The phosphoinositol-3 kinase (PI3K) pathway is frequently dysregulated in endometrial cancer (EC). | DisGeNET | Detail |
NEDD4 ubiquitin ligase is a putative oncogene in endometrial cancer that activates IGF-1R/PI3K/Akt s... | DisGeNET | Detail |
The phosphatidylinositol 3-kinase (PI3K), MAP kinase (MAPK), and related pathways are implicated in ... | DisGeNET | Detail |
NA | DisGeNET | Detail |
PI3K pathway activation in high-grade ductal carcinoma in situ--implications for progression to inva... | DisGeNET | Detail |
NA | DisGeNET | Detail |
In conclusion, the positive feedback loop between NOX4 and PI3K/Akt signaling contributes to NSCLC p... | DisGeNET | Detail |
We have recently shown that Semaphorin 4B (SEMA4B) inhibits the invasion of non-small cell lung canc... | DisGeNET | Detail |
ILT4 drives B7-H3 expression via PI3K/AKT/mTOR signalling and ILT4/B7-H3 co-expression correlates wi... | DisGeNET | Detail |
Overlapped Transcript Coordinates
Gene | Transcript ID | Exon Number | Chromosome | Start | Stop | Type | Amino Mutation | Transcript Position | Links |
---|
Overlapped Transcript
Gene | Transcript ID | Chromosome | Start | Stop | Links |
---|
- Gene
- -
- dbSNP
- rs386584794 dbSNP
- Genome
- hg38
- Position
- chr3:138,652,698-138,834,928
- Variant Type
- snv
Genome browser